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On May 14, 1796, Edward Jenner, an English physician,
inoculated James Phipps, age 8, with material from a cowpox
lesion on the hand of a milkmaid. Jenner subsequently dem-
onstrated that the child was protected against smallpox. This
procedure became known as vaccination, which resulted in the
global eradication of smallpox 181 years later.
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Introduction
This report provides technical guidance regarding common
immunization concerns for health-care providers who admin-
ister vaccines to children, adolescents, and adults. Vaccine rec-
ommendations are based on characteristics of the
immunobiologic product, scientific knowledge regarding the
principles of active and passive immunization, the epidemiol-
ogy and burden of diseases (i.e., morbidity, mortality, costs of
treatment, and loss of productivity), the safety of vaccines,
and the cost analysis of preventive measures as judged by pub-
lic health officials and specialists in clinical and preventive
medicine.
Benefits and risks are associated with using all
immunobiologics. No vaccine is completely safe or 100% ef-
fective. Benefits of vaccination include partial or complete
protection against the consequences of infection for the vacci-
nated person, as well as overall benefits to society as a whole.
Benefits include protection from symptomatic illness, im-
proved quality of life and productivity, and prevention of death.
Societal benefits include creation and maintenance of herd im-
munity against communicable diseases, prevention of disease
outbreaks, and reduction in health-care–related costs. Vacci-
nation risks range from common, minor, and local adverse
effects to rare, severe, and life-threatening conditions. Thus,
recommendations for immunization practices balance scien-
tific evidence of benefits for each person and to society against
the potential costs and risks of vaccination programs.
Standards for child and adolescent immunization practices
and standards for adult immunization practices (1,2) have been
published to assist with implementing vaccination programs
and maximizing their benefits. Any person or institution that
provides vaccination services should adopt these standards to
improve immunization delivery and protect children, adoles-
cents, and adults from vaccine-preventable diseases.
To maximize the benefits of vaccination, this report pro-
vides general information regarding immunobiologics and
provides practical guidelines concerning vaccine administra-
tion and technique. To minimize risk from vaccine adminis-
tration, this report delineates situations that warrant
precautions or contraindications to using a vaccine. These rec-
ommendations are intended for use in the United States be-
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Summary
This report is a revision of General Recommendations on Immunization and updates the 1994 statement by the Advisory
Committee on Immunization Practices (ACIP) (CDC. General recommendations on immunization: recommendations of
the Advisory Committee on Immunization Practices [ACIP]. MMWR 1994;43[No. RR-1]:1–38). The principal changes
include expansion of the discussion of vaccination spacing and timing, recommendations for vaccinations administered by an
incorrect route, information regarding needle-free injection technology, vaccination of children adopted from countries outside the
United States, timing of live-virus vaccination and tuberculosis screening, expansion of the discussion and tables of contraindications
and precautions regarding vaccinations, and addition of a directory of immunization resources. These recommendations are not
comprehensive for each vaccine. The most recent ACIP recommendations for each specific vaccine should be consulted for addi-
tional details. This report, ACIP recommendations for each vaccine, and other information regarding immunization can be
accessed at CDC’s National Immunization Program website at http://www.cdc.gov/nip (accessed October 11, 2001).
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cause vaccine availability and use, as well as epidemiologic
circumstances, differ in other countries. Individual circum-
stances might warrant deviations from these recommenda-
tions. The relative balance of benefits and risks can change
as diseases are controlled or eradicated. For example, be-
cause wild poliovirus transmission has been interrupted in
the United States since 1979, the only indigenous cases of
paralytic poliomyelitis reported since that time have been
caused by live oral poliovirus vaccine (OPV). In 1997, to
reduce the risk for vaccine-associated paralytic polio (VAPP),
increased use of inactivated poliovirus vaccine (IPV) was
recommended in the United States (3). In 1999, to elimi-
nate the risk for VAPP, exclusive use of IPV was recommended
for routine vaccination in the United States (4), and OPV
subsequently became unavailable for routine use. However,
because of superior ability to induce intestinal immunity
and to prevent spread among close contacts, OPV remains
the vaccine of choice for areas where wild poliovirus is still
present. Until worldwide eradication of poliovirus is accom-
plished, continued vaccination of the U.S. population against
poliovirus will be necessary.
Timing and Spacing
of Immunobiologics
General Principles
for Vaccine Scheduling
Optimal response to a vaccine depends on multiple fac-
tors, including the nature of the vaccine and the age and
immune status of the recipient. Recommendations for the
age at which vaccines are administered are influenced by
age-specific risks for disease, age-specific risks for complica-
tions, ability of persons of a certain age to respond to the
vaccine, and potential interference with the immune re-
sponse by passively transferred maternal antibody. Vaccines
are recommended for members of the youngest age group
at risk for experiencing the disease for whom efficacy and
safety have been demonstrated.
Certain products, including inactivated vaccines, toxoids,
recombinant subunit and polysaccharide conjugate vaccines,
require administering >2 doses for development of an adequate
and persisting antibody response. Tetanus and diphtheria tox-
oids require periodic reinforcement or booster doses to main-
tain protective antibody concentrations. Unconjugated
polysaccharide vaccines do not induce T-cell memory, and
booster doses are not expected to produce substantially in-
creased protection. Conjugation with a protein carrier improves
the effectiveness of polysaccharide vaccines by inducing T-cell–
dependent immunologic function. Vaccines that stimulate both
cell-mediated immunity and neutralizing antibodies (e.g.,
live attenuated virus vaccines) usually can induce prolonged,
often lifelong immunity, even if antibody titers decline as
time progresses (5). Subsequent exposure to infection usu-
ally does not lead to viremia but to a rapid anamnestic
antibody response.
Approximately 90%–95% of recipients of a single dose of a
parenterally administered live vaccine at the recommended age
(i.e., measles, mumps, rubella [MMR], varicella, and yellow
fever), develop protective antibody within 2 weeks of the dose.
However, because a limited proportion of recipients (<5%) of
MMR vaccine fail to respond to one dose, a second dose is
recommended to provide another opportunity to develop im-
munity (6). The majority of persons who fail to respond to
the first dose of MMR respond to a second dose (7). Similarly,
approximately 20% of persons aged >13 years fail to respond
to the first dose of varicella vaccine; 99% of recipients
seroconvert after two doses (8).
The recommended childhood vaccination schedule is re-
vised annually and is published each January. Recommen-
dations for vaccination of adolescents and adults are revised
less frequently, except for influenza vaccine recommenda-
tions, which are published annually. Physicians and other
health-care providers should always ensure that they are
following the most up-to-date schedules, which are avail-
able from CDC’s National Immunization Program website
at http://www.cdc.gov/nip (accessed October 11, 2001).
Spacing of Multiple Doses
of the Same Antigen
Vaccination providers are encouraged to adhere as closely
as possible to the recommended childhood immunization
schedule. Clinical studies have reported that recommended
ages and intervals between doses of multidose antigens pro-
vide optimal protection or have the best evidence of effi-
cacy. Recommended vaccines and recommended intervals
between doses are provided in this report (Table 1).
In certain circumstances, administering doses of a
multidose vaccine at shorter than the recommended inter-
vals might be necessary. This can occur when a person is
behind schedule and needs to be brought up-to-date as
quickly as possible or when international travel is impend-
ing. In these situations, an accelerated schedule can be used
that uses intervals between doses shorter than those recom-
mended for routine vaccination. Although the effectiveness
of all accelerated schedules has not been evaluated in clini-
cal trials, the Advisory Committee on Immunization Prac-
tices (ACIP) believes that the immune response when
accelerated intervals are used is acceptable and will lead to
adequate protection. The accelerated, or minimum, inter-
Vol. 51 / RR-2 Recommendations and Reports 3
TABLE 1. Recommended and minimum ages and intervals between vaccine doses*
Vaccine Recommended age Minimum age Recommended Minimum
and dose number for this dose for this dose interval to next dose interval to next dose
Hepatitis B1† Birth–2 mos Birth 1–4 mos 4 wks
Hepatitis B2 1–4 mos 4 weeks 2–17 mos 8 wks
Hepatitis B3§ 6–18 mos 6 mos¶ — —
Diphtheria and tetanus 2 mos 6 wks 2 mos 4 wks
toxoids and acellular
pertussis (DTaP)1
DTaP2 4 mos 10 wks 2 mos 4 wks
DTaP3 6 mos 14 wks 6–12 mos 6 mos¶**
DTaP4 15–18 mos 12 mos 3 yrs 6 mos¶
DTaP5 4–6 yrs 4 yrs — —
Haemophilus influenzae, 2 mos 6 wks 2 mos 4 wks
type b (Hib)1† ††
Hib2 4 mos 10 wks 2 mos 4 wks
Hib3§§ 6 mos 14 wks 6–9 mos 8 wks
Hib4 12–15 mos 12 mos — —
Inactivated poliovirus 2 mos 6 wks 2 mos 4 wks
vaccine (IPV)1
IPV2 4 mos 10 wks 2–14 mos 4 wks
IPV3 6–18 mos 14 wks 3.5 yrs 4 wks
IPV4 4–6 yrs 18 wks — —
Pneumococcal conjugate 2 mos 6 wks 2 mos 4 wks
vaccine (PCV)1††
PCV2 4 mos 10 wks 2 mos 4 wks
PCV3 6 mos 14 wks 6 mos 8 wks
PCV4 12–15 mos 12 mos — —
Measles, mumps, and 12–15 mos¶¶ 12 mos 3–5 yrs 4 wks
rubella (MMR)1
MMR2 4–6 yrs 13 mos — —
Varicella*** 12–15 mos 12 mos 4 wks*** 4 wks***
Hepatitis A1 >2 yrs 2 yrs 6–18 mos¶ 6 mos¶
Hepatitis A2 >30 mos 30 mos — —
Influenza††† — 6 mos¶ 1 mo 4 wks
pneumococcal — 2 yrs 5 yrs§§§ 5 yrs
polysaccharide (PPV)1
PPV2 — 7 yrs§§§ — —
* Combination vaccines are available. Using licensed combination vaccines is preferred over separate injections of their equivalent component vaccines (Source: CDC. Combi-
nation vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and
the American Academy of Family Physicians (AAFP). MMWR 1999;48[No. RR-5]:5). When administering combination vaccines, the minimum age for administration is the
oldest age for any of the individual components; the minimum interval between doses is equal to the greatest interval of any of the individual antigens.
† A combination hepatitis B-Hib vaccine is available (Comvax®, manufactured by Merck Vaccine Division). This vaccine should not be administered to infants aged <6 weeks
because of the Hib component.
§ Hepatitis B3 should be administered >8 weeks after Hepatitis B2 and 16 weeks after Hepatitis B1, and it should not be administered before age 6 months.
¶ Calendar months.
** The minimum interval between DTaP3 and DTaP4 is recommended to be >6 months. However, DTaP4 does not need to be repeated if administered >4 months after DTaP3.
†† For Hib and PCV, children receiving the first dose of vaccine at age >7 months require fewer doses to complete the series (see CDC. Haemophilus b conjugate vaccines for
prevention of Haemophilus influenzae, type b disease among infants and children two months of age and older: recommendations of the ACIP. MMWR 1991;40[No. RR-1]:1–7,
and CDC. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR
2000;49[No. RR-9]:1–35).
§§ For a regimen of only polyribosylribitol phosphate-meningococcal outer membrane protein (PRP-OMP, PedvaxHib®, manufactured by Merck), a dose administered at age 6
months is not required.
¶¶ During a measles outbreak, if cases are occurring among infants aged <12 months, measles vaccination of infants aged >6 months can be undertaken as an outbreak control
measure. However, doses administered at age <12 months should not be counted as part of the series (Source: CDC. Measles, mumps, and rubella — vaccine use and
strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices
[ACIP]. MMWR 1998;47[No. RR-8]:1–57).
*** Children aged 12 months–13 years require only one dose of varicella vaccine. Persons aged >13 years should receive two doses separated by >4 weeks.
††† Two doses of inactivated influenza vaccine, separated by 4 weeks, are recommended for children aged 6 months–9 years who are receiving the vaccine for the first time.
Children aged 6 months–9 years who have previously received influenza vaccine and persons aged >9 years require only one dose per influenza season.
§§§ Second doses of PPV are recommended for persons at highest risk for serious pneumococcal infection and those who are likely to have a rapid decline in pneumococcal antibody
concentration. Revaccination 3 years after the previous dose can be considered for children at highest risk for severe pneumococcal infection who would be aged <10 years at the
time of revaccination (see CDC. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1997;46[No.
RR-8]:1–24).
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vals and ages that can be used for scheduling catch-up vac-
cinations is provided in this report (Table 1). Vaccine doses
should not be administered at intervals less than these mini-
mum intervals or earlier than the minimum age.*
In clinical practice, vaccine doses occasionally are admin-
istered at intervals less than the minimum interval or at
ages younger than the minimum age. Doses administered
too close together or at too young an age can lead to a sub-
optimal immune response. However, administering a dose
a limited number of days earlier than the minimum inter-
val or age is unlikely to have a substantially negative effect
on the immune response to that dose. Therefore, ACIP rec-
ommends that vaccine doses administered <4 days before
the minimum interval or age be counted as valid.† How-
ever, because of its unique schedule, this recommendation
does not apply to rabies vaccine (9). Doses administered
>5 days earlier than the minimum interval or age should
not be counted as valid doses and should be repeated as
age-appropriate. The repeat dose should be spaced after the
invalid dose by the recommended minimum interval as
provided in this report (Table 1). For example, if Haemophilus
influenzae type b (Hib) doses one and two were adminis-
tered only 2 weeks apart, dose two is invalid and should be
repeated. The repeat dose should be administered >4 weeks
after the invalid (second) dose. The repeat dose would be
counted as the second valid dose. Doses administered >5
days before the minimum age should be repeated on or
after the child reaches the minimum age and >4 weeks after
the invalid dose. For example, if varicella vaccine were ad-
ministered at age 10 months, the repeat dose would be
administered no earlier than the child’s first birthday.
Certain vaccines produce increased rates of local or systemic
reactions in certain recipients when administered too frequently
(e.g., adult tetanus-diphtheria toxoid [Td], pediatric
diphtheria-tetanus toxoid [DT], and tetanus toxoid) (10,11).
Such reactions are thought to result from the formation of
antigen-antibody complexes. Optimal record keeping, main-
taining patient histories, and adhering to recommended sched-
ules can decrease the incidence of such reactions without
adversely affecting immunity.
Simultaneous Administration
Experimental evidence and extensive clinical experience
have strengthened the scientific basis for administering vac-
cines simultaneously (i.e., during the same office visit, not
combined in the same syringe). Simultaneously adminis-
tering all vaccines for which a person is eligible is critical,
including for childhood vaccination programs, because si-
multaneous administration increases the probability that a
child will be fully immunized at the appropriate age. A
study conducted during a measles outbreak demonstrated
that approximately one third of measles cases among un-
vaccinated but vaccine-eligible preschool children could have
been prevented if MMR had been administered at the same
visit when another vaccine was administered (12). Simulta-
neous administration also is critical when preparing for for-
eign travel and if uncertainty exists that a person will return
for further doses of vaccine.
Simultaneously administering the most widely used live and
inactivated vaccines have produced seroconversion rates and
rates of adverse reactions similar to those observed when the
vaccines are administered separately (13–16). Routinely ad-
ministering all vaccines simultaneously is recommended for
children who are the appropriate age to receive them and for
whom no specific contraindications exist at the time of the
visit. Administering combined MMR vaccine yields results
similar to administering individual measles, mumps, and ru-
bella vaccines at different sites. Therefore, no medical basis
exists for administering these vaccines separately for routine
vaccination instead of the preferred MMR combined vaccine
(6). Administering separate antigens would result in a delay in
protection for the deferred components. Response to MMR
and varicella vaccines administered on the same day is identi-
cal to vaccines administered a month apart (17). No evidence
exists that OPV interferes with parenterally administered live
vaccines. OPV can be administered simultaneously or at any
interval before or after parenteral live vaccines. No data exist
regarding the immunogenicity of oral Ty21a typhoid vaccine
when administered concurrently or within 30 days of live vi-
rus vaccines. In the absence of such data, if typhoid vaccina-
tion is warranted, it should not be delayed because of
administration of virus vaccines (18).
Simultaneously administering pneumococcal polysaccharide
vaccine and inactivated influenza vaccine elicits a satisfactory
antibody response without increasing the incidence or severity
of adverse reactions (19). Simultaneously administering pneu-
mococcal polysaccharide vaccine and inactivated influenza
* During measles outbreaks, if cases are occurring among infants aged <12
months, measles vaccination of infants as young as 6 months can be undertaken
as an outbreak control measure. However, doses administered at ages <12
months should not be counted as part of the series (Source: CDC. Measles,
mumps, and rubella — vaccine use and strategies for elimination of measles,
rubella, and congenital rubella syndrome and control of mumps:
recommendations of the Advisory Committee on Immunization Practices
[ACIP]. MMWR 1998;47[No. RR-8]:1–57).
† In certain situations, local or state requirements might mandate that doses of
selected vaccines be administered on or after specific ages. For example, a
school entry requirement might not accept a dose of MMR or varicella vaccine
administered before the child’s first birthday. ACIP recommends that physicians
and other health-care providers comply with local or state vaccination
requirements when scheduling and administering vaccines.
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vaccine is strongly recommended for all persons for whom
both vaccines are indicated.
Hepatitis B vaccine administered with yellow fever vaccine
is as safe and immunogenic as when these vaccines are admin-
istered separately (20). Measles and yellow fever vaccines
have been administered safely at the same visit and without
reduction of immunogenicity of each of the components
(21,22).
Depending on vaccines administered in the first year of life,
children aged 12–15 months can receive <7 injections during
a single visit (MMR, varicella, Hib, pneumococcal conjugate,
diphtheria and tetanus toxoids and acellular pertussis [DTaP],
IPV, and hepatitis B vaccines). To help reduce the number of
injections at the 12–15-month visit, the IPV primary series
can be completed before the child’s first birthday. MMR and
varicella vaccines should be administered at the same visit that
occurs as soon as possible on or after the first birthday. The
majority of children aged 1 year who have received two
(polyribosylribitol phosphate-meningococcal outer membrane
protein [PRP-OMP]) or three (PRP-tetanus [PRP-T], diph-
theria CRM
197
 [CRM, cross-reactive material] protein conju-
gate [HbOC]) prior doses of Hib vaccine, and three prior doses
of DTaP and pneumococcal conjugate vaccine have developed
protection (23,24). The third (PRP-OMP) or fourth (PRP-T,
HbOC) dose of the Hib series, and the fourth doses of DTaP
and pneumococcal conjugate vaccines are critical in boosting
antibody titer and ensuring continued protection (24–26).
However, the booster dose of the Hib or pneumococcal con-
jugate series can be deferred until ages 15–18 months for chil-
dren who are likely to return for future visits. The fourth dose
of DTaP is recommended to be administered at ages 15–18
months, but can be administered as early as age 12 months
under certain circumstances (25). For infants at low risk for
infection with hepatitis B virus (i.e., the mother tested nega-
tive for hepatitis B surface antigen [HBsAg] at the time of
delivery and the child is not of Asian or Pacific Islander de-
scent), the hepatitis B vaccine series can be completed at any
time during ages 6–18 months. Recommended spacing of doses
should be maintained (Table 1).
Use of combination vaccines can reduce the number of
injections required at an office visit. Licensed combination
vaccines can be used whenever any components of the com-
bination are indicated and its other components are not
contraindicated. Use of licensed combination vaccines is
preferred over separate injection of their equivalent compo-
nent vaccines (27). Only combination vaccines approved
by the Food and Drug Administration (FDA) should be
used. Individual vaccines must never be mixed in the same
syringe unless they are specifically approved for mixing by
FDA. Only one vaccine (DTaP and PRP-T Hib vaccine,
marketed as TriHIBit® [manufactured by Aventis Pasteur])
is FDA-approved for mixing in the same syringe. This vac-
cine should not be used for primary vaccination in infants
aged 2, 4, and 6 months, but it can be used as a booster
after any Hib vaccine.
Nonsimultaneous Administration
Inactivated vaccines do not interfere with the immune
response to other inactivated vaccines or to live vaccines.
An inactivated vaccine can be administered either simulta-
neously or at any time before or after a different inactivated
vaccine or live vaccine (Table 2).
The immune response to one live-virus vaccine might be
impaired if administered within 30 days of another live-
virus vaccine (28,29). Data are limited concerning inter-
ference between live vaccines. In a study conducted in two
U.S. health maintenance organizations, persons who received
varicella vaccine <30 days after MMR vaccination had an
increased risk for varicella vaccine failure (i.e., varicella dis-
ease in a vaccinated person) of 2.5-fold compared with those
who received varicella vaccine before or >30 days after MMR
(30). In contrast, a 1999 study determined that the re-
sponse to yellow fever vaccine is not affected by monova-
lent measles vaccine administered 1–27 days earlier (21).
The effect of nonsimultaneously administering rubella,
mumps, varicella, and yellow fever vaccines is unknown.
To minimize the potential risk for interference, parenter-
ally administered live vaccines not administered on the same
day should be administered >4 weeks apart whenever pos-
sible (Table 2). If parenterally administered live vaccines
are separated by <4 weeks, the vaccine administered sec-
ond should not be counted as a valid dose and should be
repeated. The repeat dose should be administered >4 weeks
after the last, invalid dose. Yellow fever vaccine can be ad-
ministered at any time after single-antigen measles vaccine.
Ty21a typhoid vaccine and parenteral live vaccines (i.e.,
TABLE 2. Guidelines for spacing of live and inactivated
antigens
Antigen Recommended minimum interval
combination between doses
>2 inactivated None; can be administered simultaneously
or at any interval between doses
Inactivated and live None; can be administered simultaneously
or at any interval between doses
>2 live parenteral* 4-week minimum interval, if not administered
 simultaneously
* Live oral vaccines (e.g., Ty21a typhoid vaccine, oral polio vaccine) can be
administered simultaneously or at any interval before or after inactivated
or live parenteral vaccines.
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MMR, varicella, yellow fever) can be administered simul-
taneously or at any interval before or after each other, if
indicated.
Spacing of Antibody-Containing
Products and Vaccines
Live Vaccines
Ty21a typhoid and yellow fever vaccines can be adminis-
tered at any time before, concurrent with, or after adminis-
tering any immune globulin or hyperimmune globulin (e.g.,
hepatitis B immune globulin and rabies immune globu-
lin). Blood (e.g., whole blood, packed red blood cells, and
plasma) and other antibody-containing blood products
(e.g., immune globulin, hyperimmune globulin, and in-
travenous immune globulin [IGIV]) can inhibit the im-
mune response to measles and rubella vaccines for >3 months
(31,32). The effect of blood and immune globulin prepa-
rations on the response to mumps and varicella vaccines is
unknown, but commercial immune globulin preparations
contain antibodies to these viruses. Blood products avail-
able in the United States are unlikely to contain a substan-
tial amount of antibody to yellow fever vaccine virus. The
length of time that interference with parenteral live vacci-
nation (except yellow fever vaccine) can persist after the an-
tibody-containing product is a function of the amount of
antigen-specific antibody contained in the product (31–
33). Therefore, after an antibody-containing product is re-
ceived, parenteral live vaccines (except yellow fever vaccine)
should be delayed until the passive antibody has degraded
(Table 3). Recommended intervals between receipt of vari-
ous blood products and measles-containing vaccine and
varicella vaccine are listed in this report (Table 4). If a dose
of parenteral live-virus vaccine (except yellow fever vaccine)
is administered after an antibody-containing product but
at an interval shorter than recommended in this report, the
vaccine dose should be repeated unless serologic testing in-
dicates a response to the vaccine. The repeat dose or sero-
logic testing should be performed after the interval indicated
for the antibody-containing product (Table 4).
Although passively acquired antibodies can interfere with
the response to rubella vaccine, the low dose of anti-Rho(D)
globulin administered to postpartum women has not been
demonstrated to reduce the response to the RA27/3 strain ru-
bella vaccine (34). Because of the importance of rubella im-
munity among childbearing-age women (6,35), the
postpartum vaccination of rubella-susceptible women with
rubella or MMR vaccine should not be delayed because of
receipt of anti-Rho(D) globulin or any other blood prod-
uct during the last trimester of pregnancy or at delivery.
These women should be vaccinated immediately after de-
livery and, if possible, tested >3 months later to ensure
immunity to rubella and, if necessary, to measles (6).
Interference can occur if administering an antibody-
containing product becomes necessary after administering
MMR, its individual components, or varicella vaccine. Usu-
ally, vaccine virus replication and stimulation of immunity will
occur 1–2 weeks after vaccination. Thus, if the interval be-
TABLE 3. Guidelines for administering antibody-containing products* and vaccines
Simultaneous administration
Combination Recommended minimum interval between doses
Antibody-containing products and inactivated antigen None; can be administered simultaneously at different sites or at any
time between doses
Antibody-containing products and live antigen Should not be administered simultaneously.† If simultaneous
administration of measles-containing vaccine or varicella vaccine is
unavoidable, administer at different sites and revaccinate or test for
seroconversion after the recommended interval (see Table 4)
Nonsimultaneous administration
Product administered
First Second Recommended minimum interval between doses
Antibody-containing products Inactivated antigen None
Inactivated antigen Antibody-containing products None
Antibody-containing products Live antigen Dose-related†§
Live antigen Antibody-containing products 2 weeks
* Blood products containing substantial amounts of immunoglobulin, including intramuscular and intravenous immune globulin, specific hyperimmune globulin
(e.g, hepatitis B immune globulin, tetanus immune globulin, varicella zoster immune globulin, and rabies immune globulin), whole blood, packed red cells,
plasma, and platelet products.
† Yellow fever and oral Ty21a typhoid vaccines are exceptions to these recommendations. These live attenuated vaccines can be administered at any time
before, after, or simultaneously with an antibody-containing product without substantially decreasing the antibody response.§ The duration of interference of antibody-containing products with the immune response to the measles component of measles-containing vaccine, and
possibly varicella vaccine, is dose-related (see Table 4).
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tween administering any of these vaccines and subsequent
administration of an antibody-containing product is <14
days, vaccination should be repeated after the recommended
interval (Tables 3,4), unless serologic testing indicates that
antibodies were produced.
A humanized mouse monoclonal antibody product
(palivizumab) is available for prevention of respiratory syn-
cytial virus infection among infants and young children.
This product contains only antibody to respiratory syncy-
tial virus; hence, it will not interfere with immune response
to live or inactivated vaccines.
Inactivated Vaccines
Antibody-containing products interact less with inacti-
vated vaccines, toxoids, recombinant subunit, and polysac-
charide vaccines than with live vaccines (36). Therefore,
administering inactivated vaccines and toxoids either simul-
taneously with or at any interval before or after receipt of an
antibody-containing product should not substantially im-
pair development of a protective antibody response (Table
3). The vaccine or toxoid and antibody preparation should
be administered at different sites by using the standard rec-
TABLE 4. Suggested intervals between administration of antibody-containing products for different indications and measles-
containing vaccine and varicella vaccine*
Dose, including mg Recommended interval
immunoglobulin G (IgG)/kg before measles or varicella
Product/Indication body weight* vaccination (months)
Respiratory syncytial virus immune globulin 15 mg/kg intramuscularly (IM) None
(IG) monoclonal antibody (Synagis™)†
Tetanus IG 250 units (10 mg IgG/kg) IM 3
Hepatitis A IG
Contact prophylaxis 0.02 mL/kg (3.3 mg IgG/kg) IM 3
International travel 0.06 mL/kg (10 mg IgG/kg) IM 3
Hepatitis B IG 0.06 mL/kg (10 mg IgG/kg) IM 3
Rabies IG 20 IU/kg (22 mg IgG/kg) IM 4
Varicella IG 125 units/10 kg (20–40 mg IgG/kg) IM, 5
maximum 625 units
Measles prophylaxis IG
Standard (i.e., nonimmuno-compromised) contact 0.25 mL/kg (40 mg IgG/kg) IM 5
Immunocompromised contact 0.50 mL/kg (80 mg IgG/kg) IM 6
Blood transfusion
Red blood cells (RBCs), washed 10 mL/kg negligible IgG/kg None
intravenously (IV)
RBCs, adenine-saline added 10 mL/kg (10 mg IgG/kg) IV 3
Packed RBCs (hematocrit 65%)§ 10 mL/kg (60 mg IgG/kg) IV 6
Whole blood (hematocrit 35%–50%)§ 10 mL/kg (80–100 mg IgG/kg) IV 6
Plasma/platelet products 10 mL/kg (160 mg IgG/kg) IV 7
Cytomegalovirus intravenous immune 150 mg/kg maximum 6
globulin (IGIV)
Respiratory syncytial virus prophylaxis IGIV 750 mg/kg 9
IGIV
Replacement therapy for immune deficiencies¶ 300–400 mg/kg IV¶ 8
Immune thrombocytopenic purpura 400 mg/kg IV 8
Immune thrombocytopenic purpura 1,000 mg/kg IV 10
 Kawasaki disease 2 grams/kg IV 11
* This table is not intended for determining the correct indications and dosages for using antibody-containing products. Unvaccinated persons might not be
fully protected against measles during the entire recommended interval, and additional doses of immune globulin or measles vaccine might be indicated
after measles exposure. Concentrations of measles antibody in an immune globulin preparation can vary by manufacturer’s lot. Rates of antibody clearance
after receipt of an immune globulin preparation might vary also. Recommended intervals are extrapolated from an estimated half-life of 30 days for
passively acquired antibody and an observed interference with the immune response to measles vaccine for 5 months after a dose of 80 mg IgG/kg
(Source: Mason W, Takahashi M, Schneider T. Persisting passively acquired measles antibody following gamma globulin therapy for Kawasaki disease
and response to live virus vaccination [Abstract 311]. Presented at the 32nd meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy,
Los Angeles, California, October 1992).
† Contains antibody only to respiratory syncytial virus.§ Assumes a serum IgG concentration of 16 mg/mL.
¶ Measles and varicella vaccination is recommended for children with asymptomatic or mildly symptomatic human immunodeficiency virus (HIV) infection but
is contraindicated for persons with severe immunosuppression from HIV or any other immunosuppressive disorder.
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ommended dose. Increasing the vaccine dose volume or
number of vaccinations is not indicated or recommended.
Interchangeability of Vaccines
from Different Manufacturers
Numerous vaccines are available from different manufac-
turers, and these vaccines usually are not identical in anti-
gen content or amount or method of formulation.
Manufacturers use different production processes, and their
products might contain different concentrations of antigen
per dose or different stabilizers or preservatives.
Available data indicate that infants who receive sequen-
tial doses of different Hib conjugate, hepatitis B, and hepa-
titis A vaccines produce a satisfactory antibody response after
a complete primary series (37–40). All brands of Hib con-
jugate, hepatitis B,§ and hepatitis A vaccines are interchange-
able within their respective series. If different brands of Hib
conjugate vaccine are administered, a total of three doses is
considered adequate for the primary series among infants.
After completing the primary series, any Hib conjugate vac-
cine can be used for the booster dose at ages 12–18 months.
Data are limited regarding the safety, immunogenicity,
and efficacy of using acellular pertussis (as DTaP) vaccines
from different manufacturers for successive doses of the per-
tussis series. Available data from one study indicate that,
for the first three doses of the DTaP series, one or two doses
of Tripedia® (manufactured by Aventis Pasteur) followed by
Infanrix® (manufactured by GlaxoSmithKline) for the re-
maining doses(s) is comparable to three doses of Tripedia
with regard to immunogenicity, as measured by antibodies
to diphtheria, tetanus, and pertussis toxoid, and filamen-
tous hemagglutinin (41). However, in the absence of a clear
serologic correlate of protection for pertussis, the relevance
of these immunogenicity data for protection against per-
tussis is unknown. Whenever feasible, the same brand of
DTaP vaccine should be used for all doses of the vaccina-
tion series; however, vaccination providers might not know
or have available the type of DTaP vaccine previously ad-
ministered to a child. In this situation, any DTaP vaccine
should be used to continue or complete the series. Vaccina-
tion should not be deferred because the brand used for pre-
vious doses is not available or is unknown (25,42).
Lapsed Vaccination Schedule
Vaccination providers are encouraged to administer vac-
cines as close to the recommended intervals as possible.
However, longer-than-recommended intervals between
doses do not reduce final antibody concentrations, although
protection might not be attained until the recommended
number of doses has been administered. An interruption in
the vaccination schedule does not require restarting the entire
series of a vaccine or toxoid or the addition of extra doses.
Unknown or Uncertain
Vaccination Status
Vaccination providers frequently encounter persons who
do not have adequate documentation of vaccinations. Pro-
viders should only accept written, dated records as evidence
of vaccination. With the exception of pneumococcal polysac-
charide vaccine (43), self-reported doses of vaccine without
written documentation should not be accepted. Although
vaccinations should not be postponed if records cannot be
found, an attempt to locate missing records should be made
by contacting previous health-care providers and searching
for a personally held record. If records cannot be located,
these persons should be considered susceptible and should
be started on the age-appropriate vaccination schedule. Se-
rologic testing for immunity is an alternative to vaccination
for certain antigens (e.g., measles, mumps, rubella, vari-
cella, tetanus, diphtheria, hepatitis A, hepatitis B, and po-
liovirus) (see Vaccination of Internationally Adopted
Children).
Contraindications and Precautions
Contraindications and precautions to vaccination dictate
circumstances when vaccines will not be administered. The
majority of contraindications and precautions are temporary,
and the vaccination can be administered later. A contraindica-
tion is a condition in a recipient that increases the risk for a
serious adverse reaction. A vaccine will not be administered
when a contraindication is present. For example, administer-
ing influenza vaccine to a person with an anaphylactic allergy
to egg protein could cause serious illness in or death of the
recipient.
National standards for pediatric immunization practices
have been established and include true contraindications
and precautions to vaccination (Table 5) (1). The only true
contraindication applicable to all vaccines is a history of a
severe allergic reaction after a prior dose of vaccine or to a
vaccine constituent (unless the recipient has been desensi-
tized). Severely immunocompromised persons should not
receive live vaccines. Children who experience an encephal-
opathy <7 days after administration of a previous dose of
diphtheria and tetanus toxoids and whole-cell pertussis vac-
§ The exception is the two-dose hepatitis B vaccination series for adolescents
aged 11–15 years. Only Recombivax HB® (Merck Vaccine Division) should
be used in this schedule. Engerix-B® is not approved by FDA for this schedule.
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TABLE 5. Guide to contraindications and precautions* to commonly used vaccines
 Vaccine True contraindications and precautions* Untrue (vaccines can be administered)
General for all vaccines, including
diphtheria and tetanus toxoids
and acellular pertussis vaccine
(DTaP); pediatric diphtheria-
tetanus toxoid (DT); adult tetanus-
diphtheria toxoid (Td); inactivated
poliovirus vaccine (IPV); measles-
mumps-rubella vaccine (MMR);
Haemophilus influenzae  type b
vaccine (Hib); hepatitis A vaccine;
hepatitis B vaccine; varicella
vaccine; pneumococcal conjugate
vaccine (PCV); influenza vaccine;
and pneumococcal polysaccha-
ride vaccine (PPV)
—
DTaP
DT, Td
Contraindications
Serious allergic reaction (e.g., anaphylaxis) after a
previous vaccine dose
Serious allergic reaction (e.g., anaphylaxis) to a vaccine
component
Precautions
Moderate or severe acute illness with or without fever
Mild acute illness with or without fever
Mild to moderate local reaction (i.e., swelling, redness,
soreness); low-grade or moderate fever after previous
dose
Lack of previous physical examination in well-appearing
person
Current antimicrobial therapy
Convalescent phase of illness
Premature birth (hepatitis B vaccine is an exception in
certain circumstances)†
Recent exposure to an infectious disease
History of penicillin allergy, other nonvaccine allergies,
relatives with allergies, receiving allergen extract
immunotherapy
Contraindications
Severe allergic reaction after a previous dose or to a
vaccine component
Encephalopathy (e.g., coma, decreased level of
consciousness; prolonged seizures) within 7 days of
administration of previous dose of DTP or DTaP
Progressive neurologic disorder, including infantile
spasms, uncontrolled epilepsy, progressive encephal-
opathy: defer DTaP until neurologic status clarified and
stabilized.
Precautions
Fever of >40.5°C <48 hours after vaccination with a
previous dose of DTP or DTaP
Collapse or shock-like state (i.e., hypotonic
hyporesponsive episode) <48 hours after receiving a
previous dose of DTP/DTaP
Seizure <3 days of receiving a previous dose of DTP/
DTaP§
Persistent, inconsolable crying lasting >3 hours <48
hours after receiving a previous dose of DTP/DTaP
Moderate or severe acute illness with or without fever
Temperature of <40.5°C, fussiness or mild drowsiness
after a previous dose of diphtheria toxoid-tetanus
toxoid-pertussis vaccine (DTP)/DTaP
Family history of seizures§
Family history of sudden infant death syndrome
Family history of an adverse event after DTP or DTaP
administration
Stable neurologic conditions (e.g., cerebral palsy, well-
controlled convulsions, developmental delay)
IPV
Contraindications
Severe allergic reaction after a previous dose or to a
vaccine component
Precautions
Guillain-Barré syndrome <6 weeks after previous dose
of tetanus toxoid-containing vaccine
Moderate or severe acute illness with or without fever
MMR¶
Contraindications
Severe allergic reaction to previous dose or vaccine
component
Precautions
Pregnancy
Moderate or severe acute illness with or without fever
Contraindications
Severe allergic reaction after a previous dose or to a
vaccine component
Pregnancy
Known severe immunodeficiency (e.g., hematologic
and solid tumors; congenital immunodeficiency; long-
term immunosuppressive therapy,** or severely
symptomatic human immunodeficiency virus [HIV]
infection)
Precautions
Recent (<11 months) receipt of antibody-containing
blood product (specific interval depends on product)§§
History of thrombocytopenia or thrombocytopenic
purpura
Moderate or severe acute illness with or without fever
Positive tuberculin skin test
Simultaneous TB skin testing††
Breast-feeding
Pregnancy of recipient’s mother or other close or
household contact
Recipient is child-bearing–age female
Immunodeficient family member or household contact
Asymptomatic or mildly symptomatic HIV infection
Allergy to eggs
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cine (DTP) or DTaP not attributable to another identifi-
able cause should not receive further doses of a vaccine that
contains pertussis. Because of the theoretical risk to the
fetus, women known to be pregnant should not receive live
attenuated virus vaccines (see Vaccination During
Pregnancy).
A precaution is a condition in a recipient that might in-
crease the risk for a serious adverse reaction or that might
compromise the ability of the vaccine to produce immu-
nity (e.g., administering measles vaccine to a person with
passive immunity to measles from a blood transfusion). In-
jury could result, or a person might experience a more se-
Contraindication
Severe allergic reaction after a previous dose or to a
vaccine component
Precautions
Infant weighing <2,000 grams†
Moderate or severe acute illness with or without fever
* Events or conditions listed as precautions should be reviewed carefully. Benefits and risks of administering a specific vaccine to a person under these circumstances should be
considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered. If the benefit of vaccination is believed to outweigh the risk, the
vaccine should be administered. Whether and when to administer DTaP to children with proven or suspected underlying neurologic disorders should be decided on a case-by-case
basis.
† Hepatitis B vaccination should be deferred for infants weighing <2,000 grams if the mother is documented to be hepatitis B surface antigen (HbsAg)-negative at the time of the
infant’s birth. Vaccination can commence at chronological age 1 month. For infants born to HbsAg-positive women, hepatitis B immunoglobulin and hepatitis B vaccine should be
administered at or soon after birth regardless of weight. See text for details.
§ Acetaminophen or other appropriate antipyretic can be administered to children with a personal or family history of seizures at the time of DTaP vaccination and every 4–6 hours
for 24 hours thereafter to reduce the possibility of postvaccination fever (Source: American Academy of Pediatrics. Active immunization. In: Pickering LK, ed. 2000 red book: report
of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000).
¶ MMR and varicella vaccines can be administered on the same day. If not administered on the same day, these vaccines should be separated by >28 days.
** Substantially immunosuppressive steroid dose is considered to be >2 weeks of daily receipt of 20 mg or 2 mg/kg body weight of prednisone or equivalent.
†† Measles vaccination can suppress tuberculin reactivity temporarily. Measles-containing vaccine can be administered on the same day as tuberculin skin testing. If testing cannot
be performed until after the day of MMR vaccination, the test should be postponed for >4 weeks after the vaccination. If an urgent need exists to skin test, do so with the
understanding that reactivity might be reduced by the vaccine.
§§ See text for details.
¶¶ If a vaccinee experiences a presumed vaccine-related rash 7–25 days after vaccination, avoid direct contact with immunocompromised persons for the duration of the rash.
Pregnancy of recipient’s mother or other close or
household contact
Immunodeficient family member or household contact¶¶
Asymptomatic or mildly symptomatic HIV infection
Humoral immunodeficiency (e.g., agammaglobulinemia)
Hib
TABLE 5. (Continued ) Guide to contraindications and precautions* to commonly used vaccines
 Vaccine True contraindications and precautions* Untrue (vaccines can be administered)
Hepatitis B
—Contraindications
Severe allergic reaction after a previous dose or to a
vaccine component
Age <6 weeks
Precaution
Moderate or severe acute illness with or without fever
Hepatitis A
Pregnancy
Autoimmune disease (e.g., systemic lupus
erythematosis or rheumatoid arthritis)
Contraindications
Severe allergic reaction after a previous dose or to a
vaccine component
Precautions
Pregnancy
Moderate or severe acute illness with or without fever
Varicella¶ Contraindications
Severe allergic reaction after a previous dose or to a
vaccine component
Substantial supression of cellular immunity
Pregnancy
Precautions
Recent (<11 months) receipt of antibody-containing
blood product (specific interval depends on product)§§
Moderate or severe acute illness with or without fever
—
PCV Contraindication
Severe allergic reaction after a previous dose or to a
vaccine component
Precaution
Moderate or severe acute illness with or without fever
Nonsevere (e.g., contact) allergy to latex or thimerosal
Concurrent administration of coumadin or aminophyl-
line
Influenza
—
Contraindication
Severe allergic reaction to previous dose or vaccine
component, including egg protein
Precautions
Moderate or severe acute illness with or without fever
PPV —Contraindication
Severe allergic reaction after a previous dose or to a
vaccine component
Precaution
Moderate or severe acute illness with or without fever
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vere reaction to the vaccine than would have otherwise been
expected; however, the risk for this happening is less than
expected with a contraindication. Under normal circum-
stances, vaccinations should be deferred when a precaution
is present. However, a vaccination might be indicated in
the presence of a precaution because the benefit of protec-
tion from the vaccine outweighs the risk for an adverse re-
action. For example, caution should be exercised in
vaccinating a child with DTaP who, within 48 hours of
receipt of a prior dose of DTP or DTaP, experienced fever
>40.5C (105F); had persistent, inconsolable crying for >3
hours; collapsed or experienced a shock-like state; or had a
seizure <3 days after receiving the previous dose of DTP or
DTaP. However, administering a pertussis-containing vac-
cine should be considered if the risk for pertussis is in-
creased (e.g., during a pertussis outbreak) (25). The presence
of a moderate or severe acute illness with or without a fever
is a precaution to administration of all vaccines. Other pre-
cautions are listed in this report (Table 5).
Physicians and other health-care providers might inap-
propriately consider certain conditions or circumstances to
be true contraindications or precautions to vaccination. This
misconception results in missed opportunities to adminis-
ter recommended vaccines (44). Likewise, physicians and
other health-care providers might fail to understand what
constitutes a true contraindication or precaution and might
administer a vaccine when it should be withheld. This prac-
tice can result in an increased risk for an adverse reaction to
the vaccine. Conditions often inappropriately regarded as
contraindications to vaccination are listed in this report (Table
5). Among the most common are diarrhea and minor upper-
respiratory tract illnesses (including otitis media) with or with-
out fever, mild to moderate local reactions to a previous dose
of vaccine, current antimicrobial therapy, and the convales-
cent phase of an acute illness.
The decision to administer or delay vaccination because of
a current or recent acute illness depends on the severity of
symptoms and the etiology of the disease. All vaccines can be
administered to persons with minor acute illness (e.g., diar-
rhea or mild upper-respiratory tract infection with or without
fever). Studies indicate that failure to vaccinate children with
minor illnesses can seriously impede vaccination efforts (45–
47). Among persons whose compliance with medical care can-
not be ensured, use of every opportunity to provide
appropriate vaccinations is critical.
The majority of studies support the safety and efficacy of
vaccinating persons who have mild illness (48–50). For ex-
ample, in the United States, >97% of children with mild
illnesses produced measles antibody after vaccination (51).
Only one limited study has reported a lower rate of
seroconversion (79%) to the measles component of MMR
vaccine among children with minor, afebrile upper-respira-
tory tract infections (52). Therefore, vaccination should not
be delayed because of the presence of mild respiratory tract
illness or other acute illness with or without fever.
Persons with moderate or severe acute illness should be
vaccinated as soon as they have recovered from the acute
phase of the illness. This precaution avoids superimposing
adverse effects of the vaccine on the underlying illness or
mistakenly attributing a manifestation of the underlying
illness to the vaccine.
Routine physical examinations and measuring tempera-
tures are not prerequisites for vaccinating infants and chil-
dren who appear to be healthy. Asking the parent or guardian
if the child is ill and then postponing vaccination for those
with moderate to severe illness, or proceeding with vacci-
nation if no contraindications exist, are appropriate proce-
dures in childhood immunization programs.
A family history of seizures or other central nervous system
disorders is not a contraindication to administration of per-
tussis or other vaccines. However, delaying pertussis vaccina-
tion for infants and children with a history of previous
seizures until the child’s neurologic status has been assessed
is prudent. Pertussis vaccine should not be administered to
infants with evolving neurologic conditions until a treat-
ment regimen has been established and the condition has
stabilized (25).
Vaccine Administration
Infection Control and Sterile
Technique
Persons administering vaccines should follow necessary pre-
cautions to minimize risk for spreading disease. Hands should
be washed with soap and water or cleansed with an alcohol-
based waterless antiseptic hand rub between each patient con-
tact. Gloves are not required when administering vaccinations,
unless persons administering vaccinations are likely to come
into contact with potentially infectious body fluids or have
open lesions on their hands. Syringes and needles used for
injections must be sterile and disposable to minimize the risk
of contamination. A separate needle and syringe should be
used for each injection. Changing needles between drawing
vaccine from a vial and injecting it into a recipient is unneces-
sary. Different vaccines should never be mixed in the same
syringe unless specifically licensed for such use.
Disposable needles and syringes should be discarded in
labeled, puncture-proof containers to prevent inadvertent
needle-stick injury or reuse. Safety needles or needle-free
injection devices also can reduce the risk for injury and
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should be used whenever available (see Occupational Safety
Regulations).
Recommended Routes of Injection
and Needle Length
Routes of administration are recommended by the manu-
facturer for each immunobiologic. Deviation from the rec-
ommended route of administration might reduce vaccine
efficacy (53,54) or increase local adverse reactions (55–57).
Injectable immunobiologics should be administered where
the likelihood of local, neural, vascular, or tissue injury is
limited. Vaccines containing adjuvants should be injected
into the muscle mass; when administered subcutaneously
or intradermally, they can cause local irritation, induration,
skin discoloration, inflammation, and granuloma formation.
Subcutaneous Injections
Subcutaneous injections usually are administered at a 45-
degree angle into the thigh of infants aged <12 months and
in the upper-outer triceps area of persons aged >12 months.
Subcutaneous injections can be administered into the up-
per-outer triceps area of an infant, if necessary. A 5/8-inch,
23–25-gauge needle should be inserted into the subcuta-
neous tissue.
Intramuscular Injections
Intramuscular injections are administered at a 90-degree
angle into the anterolateral aspect of the thigh or the del-
toid muscle of the upper arm. The buttock should not be
used for administration of vaccines or toxoids because of
the potential risk of injury to the sciatic nerve (58). In ad-
dition, injection into the buttock has been associated with
decreased immunogenicity of hepatitis B and rabies vac-
cines in adults, presumably because of inadvertent subcu-
taneous injection or injection into deep fat tissue (53,59).
For all intramuscular injections, the needle should be long
enough to reach the muscle mass and prevent vaccine from
seeping into subcutaneous tissue, but not so long as to in-
volve underlying nerves and blood vessels or bone (54,60–
62). Vaccinators should be familiar with the anatomy of
the area into which they are injecting vaccine. An individual
decision on needle size and site of injection must be made
for each person on the basis of age, the volume of the mate-
rial to be administered, the size of the muscle, and the depth
below the muscle surface into which the material is to be
injected.
Although certain vaccination specialists advocate aspira-
tion (i.e., the syringe plunger pulled back before injection),
no data exist to document the necessity for this procedure.
If aspiration results in blood in the needle hub, the needle
should be withdrawn and a new site should be selected.
Infants (persons aged <12 months). Among the ma-
jority of infants, the anterolateral aspect of the thigh
provides the largest muscle mass and is therefore the rec-
ommended site for injection. For the majority of infants, a
7/8–1-inch, 22–25-gauge needle is sufficient to penetrate
muscle in the infant’s thigh.
Toddlers and Older Children (persons aged >12
months–18 years). The deltoid muscle can be used if the
muscle mass is adequate. The needle size can range from 22
to 25 gauge and from 7/8 to 1¼ inches, on the basis of the
size of the muscle. For toddlers, the anterolateral thigh can
be used, but the needle should be longer, usually 1 inch.
Adults (persons aged >18 years). For adults, the del-
toid muscle is recommended for routine intramuscular vac-
cinations. The anterolateral thigh can be used. The suggested
needle size is 1–1½ inches and 22–25 gauge.
Intradermal Injections
Intradermal injections are usually administered on the volar
surface of the forearm. With the bevel facing upwards, a 3/8–
3/4-inch, 25–27-gauge needle can be inserted into the epider-
mis at an angle parallel to the long axis of the forearm. The
needle should be inserted so that the entire bevel penetrates
the skin and the injected solution raises a small bleb. Because
of the small amounts of antigen used in intradermal vaccina-
tions, care must be taken not to inject the vaccine subcutane-
ously because it can result in a suboptimal immunologic
response.
Multiple Vaccinations
If >2 vaccine preparations are administered or if vaccine and
an immune globulin preparation are administered simulta-
neously, each preparation should be administered at a differ-
ent anatomic site. If >2 injections must be administered in a
single limb, the thigh is usually the preferred site because of
the greater muscle mass; the injections should be sufficiently
separated (i.e., >1 inch) so that any local reactions can be dif-
ferentiated (55,63). For older children and adults, the deltoid
muscle can be used for multiple intramuscular injections, if
necessary. The location of each injection should documented
in the person’s medical record.
Jet Injection
Jet injectors (JIs) are needle-free devices that drive liquid
medication through a nozzle orifice, creating a narrow stream
under high pressure that penetrates skin to deliver a drug or
vaccine into intradermal, subcutaneous, or intramuscular tis-
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sues (64,65). Increasing attention to JI technology as an
alternative to conventional needle injection has resulted from
recent efforts to reduce the frequency of needle-stick inju-
ries to health-care workers (66) and to overcome the im-
proper reuse and other drawbacks of needles and syringes
in economically developing countries (67–69). JIs have been
reported safe and effective in administering different live
and inactivated vaccines for viral and bacterial diseases (69).
The immune responses generated are usually equivalent to,
and occasionally greater than, those induced by needle in-
jection. However, local reactions or injury (e.g., redness,
induration, pain, blood, and ecchymosis at the injection
site) can be more frequent for vaccines delivered by JIs com-
pared with needle injection (65,69).
Certain JIs were developed for situations in which substan-
tial numbers of persons must be vaccinated rapidly, but per-
sonnel or supplies are insufficient to do so with conventional
needle injection. Such high-workload devices vaccinate con-
secutive patients from the same nozzle orifice, fluid pathway,
and dose chamber, which is refilled automatically from attached
vials containing <50 doses each. Since the 1950s, these devices
have been used extensively among military recruits and for
mass vaccination campaigns for disease control and eradica-
tion (64). An outbreak of hepatitis B among patients receiv-
ing injections from a multiple-use–nozzle JI was documented
(70,71), and subsequent laboratory, field, and animal studies
demonstrated that such devices could become contaminated
with blood (69,72,73).
No U.S.-licensed, high-workload vaccination devices of
unquestioned safety are available to vaccination programs.
Efforts are under way for the research and development of
new high-workload JIs using disposable-cartridge technology
that avoids reuse of any unsterilized components having con-
tact with the medication fluid pathway or patient’s blood. Until
such devices become licensed and available, the use of existing
multiple-use–nozzle JIs should be limited. Use can be consid-
ered when the theoretical risk for bloodborne disease trans-
mission is outweighed by the benefits of rapid vaccination with
limited personnel in responding to serious disease threats (e.g.,
pandemic influenza or bioterrorism event), and by any com-
peting risks of iatrogenic or occupational infections resulting
from conventional needles and syringes. Before such emer-
gency use of multiple-use–nozzle JIs, health-care workers
should consult with local, state, national, or international
health agencies or organizations that have experience in
their use.
In the 1990s, a new generation of low-workload JIs were
introduced with disposable cartridges serving as dose cham-
bers and nozzle (69). With the provision of a new sterile
cartridge for each patient and other correct use, these de-
vices avoid the safety concerns described previously for
multiple-use–nozzle devices. They can be used in accor-
dance with their labeling for intradermal, subcutaneous, or
intramuscular administration.
Methods for Alleviating Discomfort
and Pain Associated with Vaccination
Comfort measures and distraction techniques (e.g., play-
ing music or pretending to blow away the pain) might help
children cope with the discomfort associated with vaccina-
tion. Pretreatment (30-60 minutes before injection) with
5% topical lidocaine-prilocaine emulsion (EMLA® cream
or disk [manufactured by AstraZeneca LP]) can decrease
the pain of vaccination among infants by causing superfi-
cial anesthesia (74,75). Preliminary evidence indicates that
this cream does not interfere with the immune response to
MMR (76). Topical lidocaine-prilocaine emulsion should
not be used on infants aged <12 months who are receiving
treatment with methemoglobin-inducing agents because
of the possible development of methemoglobinemia (77).
Acetaminophen has been used among children to reduce
the discomfort and fever associated with vaccination (78).
However, acetaminophen can cause formation of methemo-
globin and, thus, might interact with lidocaine-prilocaine
cream, if used concurrently (77). Ibuprofen or other
nonaspirin analgesic can be used, if necessary. Use of a topi-
cal refrigerant (vapocoolant) spray can reduce the short-
term pain associated with injections and can be as effective
as lidocaine-prilocaine cream (79). Administering sweet-
tasting fluid orally immediately before injection can result
in a calming or analgesic effect among certain infants.
Nonstandard Vaccination Practices
Recommendations regarding route, site, and dosage of
immunobiologics are derived from data from clinical trials,
from practical experience, and from theoretical considerations.
ACIP strongly discourages variations from the recommended
route, site, volume, or number of doses of any vaccine.
Variation from the recommended route and site can re-
sult in inadequate protection. The immunogenicity of hepa-
titis B vaccine and rabies vaccine is substantially lower when
the gluteal rather than the deltoid site is used for adminis-
tration (53,59). Hepatitis B vaccine administered intrad-
ermally can result in a lower seroconversion rate and final
titer of hepatitis B surface antibody than when adminis-
tered by the deltoid intramuscular route (80,81). Doses of
rabies vaccine administered in the gluteal site should not
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be counted as valid doses and should be repeated. Hepati-
tis B vaccine administered by any route or site other than
intramuscularly in the anterolateral thigh or deltoid muscle
should not be counted as valid and should be repeated,
unless serologic testing indicates that an adequate response
has been achieved.
Live attenuated parenteral vaccines (e.g., MMR, varicella,
or yellow fever) and certain inactivated vaccines (e.g., IPV,
pneumococcal polysaccharide, and anthrax) are recom-
mended by the manufacturers to be administered by sub-
cutaneous injection. Pneumococcal polysaccharide and IPV
are approved for either intramuscular or subcutaneous ad-
ministration. Response to these vaccines probably will not
be affected if the vaccines are administered by the intra-
muscular rather then subcutaneous route. Repeating doses
of vaccine administered by the intramuscular route rather
than by the subcutaneous route is unnecessary.
Administering volumes smaller than those recommended
(e.g., split doses) can result in inadequate protection. Us-
ing larger than the recommended dose can be hazardous
because of excessive local or systemic concentrations of an-
tigens or other vaccine constituents. Using multiple reduced
doses that together equal a full immunizing dose or using
smaller divided doses is not endorsed or recommended. Any
vaccination using less than the standard dose should not be
counted, and the person should be revaccinated according
to age, unless serologic testing indicates that an adequate
response has been achieved.
Preventing Adverse Reactions
Vaccines are intended to produce active immunity to spe-
cific antigens. An adverse reaction is an untoward effect that
occurs after a vaccination that is extraneous to the vaccine’s
primary purpose of producing immunity. Adverse reactions
also are called vaccine side effects.
All vaccines might cause adverse reactions (82). Vaccine ad-
verse reactions are classified by three general categories: local,
systemic, and allergic. Local reactions are usually the least se-
vere and most frequent. Systemic reactions (e.g., fever) occur
less frequently than local reactions. Serious allergic reactions
(e.g., anaphylaxis) are the most severe and least frequent. Se-
vere adverse reactions are rare.
The key to preventing the majority of serious adverse reac-
tions is screening. Every person who administers vaccines
should screen patients for contraindications and precautions
to the vaccine before it is administered (Table 5). Standard-
ized screening questionnaires have been developed and are
available from certain state immunization programs and
other sources (e.g., the Immunization Action Coalition at
http://www.immunize.org [accessed October 31, 2001]).
Severe allergic reactions after vaccination are rare. How-
ever, all physicians and other health-care providers who
administer vaccines should have procedures in place for the
emergency management of a person who experiences an
anaphylactic reaction. All vaccine providers should be fa-
miliar with the office emergency plan and be certified in
cardiopulmonary resuscitation.
Syncope (vasovagal or vasodepressor reaction) can occur af-
ter vaccination, most commonly among adolescents and young
adults. During 1990–August 2001, a total of 2,269 reports to
the Vaccine Adverse Event Reporting system were coded as
syncope. Forty percent of these episodes were reported among
persons aged 10–18 years (CDC, unpublished data, 2001).
Approximately 12% of reported syncopal episodes resulted in
hospitalization because of injury or medical evaluation. Seri-
ous injury, including skull fractures and cerebral bleeding, have
been reported to result from syncopal episodes after vacci-
nation. A published review of syncope after vaccination re-
ported that 63% of syncopal episodes occurred <5 minutes
after vaccination, and 89% occurred within 15 minutes af-
ter vaccination (83). Although syncopal episodes are un-
common and serious allergic reactions are rare, certain
vaccination specialists recommend that persons be observed
for 15–20 minutes after being vaccinated, if possible (84).
If syncope develops, patients should be observed until the
symptoms resolve.
Managing Acute Vaccine Reactions
Although rare after vaccination, the immediate onset and
life-threatening nature of an anaphylactic reaction require that
personnel and facilities providing vaccinations be capable of
providing initial care for suspected anaphylaxis. Epinephrine
and equipment for maintaining an airway should be available
for immediate use.
Anaphylaxis usually begins within minutes of vaccine ad-
ministration. Rapidly recognizing and initiating treatment are
required to prevent possible progression to cardiovascular col-
lapse. If flushing, facial edema, urticaria, itching, swelling of
the mouth or throat, wheezing, difficulty breathing, or other
signs of anaphylaxis occur, the patient should be placed in a
recumbent position with the legs elevated. Aqueous epineph-
rine (1:1000) should be administered and can be repeated
within 10–20 minutes (84). A dose of diphenhydramine hy-
drochloride might shorten the reaction, but it will have
little immediate effect. Maintenance of an airway and oxy-
gen administration might be necessary. Arrangements should
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be made for immediate transfer to an emergency facility for
further evaluation and treatment.
Occupational Safety Regulations
Bloodborne diseases (e.g., hepatitis B and C and human
immunodeficiency virus [HIV]) are occupational hazards for
health-care workers. In November 2000, to reduce the in-
cidence of needle-stick injuries among health-care workers
and the consequent risk for bloodborne diseases acquired
from patients, the Needlestick Safety and Prevention Act
was signed into law. The act directed the Occupational Safety
and Health Administration (OSHA) to strengthen its ex-
isting bloodborne pathogen standards. Those standards were
revised and became effective in April 2001 (66). These fed-
eral regulations require that safer injection devices (e.g.,
needle-shielding syringes or needle-free injectors) be used
for parenteral vaccination in all clinical settings when such
devices are appropriate, commercially available, and capable
of achieving the intended clinical purpose. The rules also
require that records be kept documenting the incidence of
injuries caused by medical sharps (except in workplaces with
<10 employees) and that nonmanagerial employees be in-
volved in the evaluation and selection of safer devices to be
procured.
Needle-shielding or needle-free devices that might satisfy the
occupational safety regulations for administering parenteral
injections are available in the United States and are listed at
multiple websites (69,85–87).¶ Additional information regard-
ing implementation and enforcement of these regulations is
available at the OSHA website at http://www.osha-slc.gov/
needlesticks (accessed October 31, 2001).
Storage and Handling
of Immunobiologics
Failure to adhere to recommended specifications for stor-
age and handling of immunobiologics can reduce potency,
resulting in an inadequate immune response in the recipi-
ent. Recommendations included in a product’s package
insert, including reconstitution of the vaccine, should be
followed carefully. Vaccine quality is the shared responsi-
bility of all parties from the time the vaccine is manufac-
tured until administration. All vaccines should be inspected
upon delivery and monitored during storage to ensure that
the cold chain has been maintained. Vaccines should con-
tinue to be stored at recommended temperatures immedi-
ately upon receipt. Certain vaccines (e.g., MMR, varicella,
and yellow fever) are sensitive to increased temperature. All
other vaccines are sensitive to freezing. Mishandled vaccine
usually is not distinguishable from potent vaccine. When
in doubt regarding the appropriate handling of a vaccine,
vaccination providers should contact the manufacturer. Vac-
cines that have been mishandled (e.g., inactivated vaccines
and toxoids that have been exposed to freezing tempera-
tures) or that are beyond their expiration date should not
be administered. If mishandled or expired vaccines are ad-
ministered inadvertently, they should not be counted as
valid doses and should be repeated, unless serologic testing
indicates a response to the vaccine.
Live attenuated virus vaccines should be administered
promptly after reconstitution. Varicella vaccine must be ad-
ministered <30 minutes after reconstitution. Yellow fever vac-
cine must be used <1 hour after reconstitution. MMR vaccine
must be administered <8 hours after reconstitution. If not
administered within these prescribed time periods after recon-
stitution, the vaccine must be discarded.
The majority of vaccines have a similar appearance after
being drawn into a syringe. Instances in which the wrong
vaccine inadvertently was administered are attributable to
the practice of prefilling syringes or drawing doses of a vac-
cine into multiple syringes before their immediate need.
ACIP discourages the routine practice of prefilling syringes
because of the potential for such administration errors. To
prevent errors, vaccine doses should not be drawn into a
syringe until immediately before administration. In certain
circumstances where a single vaccine type is being used (e.g.,
in advance of a community influenza vaccination campaign),
filling multiple syringes before their immediate use can be
considered. Care should be taken to ensure that the cold
chain is maintained until the vaccine is administered. When
the syringes are filled, the type of vaccine, lot number, and
date of filling must be carefully labeled on each syringe,
and the doses should be administered as soon as possible
after filling.
Certain vaccines are distributed in multidose vials. When
opened, the remaining doses from partially used multidose
vials can be administered until the expiration date printed on
the vial or vaccine packaging, provided that the vial has been
stored correctly and that the vaccine is not visibly contami-
nated.
¶ Internet sites with device listings are identified for information purposes only.
CDC, the U.S. Public Health Service, and the Department of Health and
Human Services do not endorse any specific device or imply that the devices
listed would all satisfy the needle-stick prevention regulations.
16 MMWR February 8, 2002
Special Situations
Concurrently Administering
Antimicrobial Agents and Vaccines
With limited exceptions, using an antibiotic is not a con-
traindication to vaccination. Antimicrobial agents have no ef-
fect on the response to live attenuated vaccines, except live
oral Ty21a typhoid vaccine, and have no effect on inactivated,
recombinant subunit, or polysaccharide vaccines or toxoids.
Ty21a typhoid vaccine should not be administered to per-
sons receiving antimicrobial agents until >24 hours after
any antibiotic dose (18).
Antiviral drugs used for treatment or prophylaxis of influ-
enza virus infections have no effect on the response to inacti-
vated influenza vaccine (88). Antiviral drugs active against
herpesviruses (e.g., acyclovir or valacyclovir) might reduce the
efficacy of live attenuated varicella vaccine. These drugs should
be discontinued >24 hours before administration of varicella
vaccine, if possible.
The antimalarial drug mefloquine (Lariam® [manufactured
by Roche Laboratories, Inc.]) could affect the immune response
to oral Ty21a typhoid vaccine if both are taken simultaneously
(89,90). To minimize this effect, administering Ty21a typhoid
vaccine >24 hours before or after a dose of mefloquine is
prudent.
Tuberculosis Screening
and Skin Test Reactivity
Measles illness, severe acute or chronic infections, HIV
infection, and malnutrition can create an anergic state dur-
ing which the tuberculin skin test (usually known as puri-
fied protein derivative [PPD] skin test) might give a false
negative reaction (91–93). Although any live attenuated
measles vaccine can theoretically suppress PPD reactivity,
the degree of suppression is probably less than that occur-
ring from acute infection from wild measles virus. Although
routine PPD screening of all children is no longer recom-
mended, PPD screening is sometimes needed at the same
time as administering a measles-containing vaccine (e.g.,
for well-child care, school entrance, or for employee health
reasons), and the following options should be considered:
• PPD and measles-containing vaccine can be adminis-
tered at the same visit (preferred option). Simultaneously
administering PPD and measles-containing vaccine does
not interfere with reading the PPD result at 48–72 hours
and ensures that the person has received measles vaccine.
• If the measles-containing vaccine has been administered
recently, PPD screening should be delayed >4 weeks
after vaccination. A delay in performing PPD will re-
move the concern of any theoretical but transient sup-
pression of PPD reactivity from the vaccine.
• PPD screening can be performed and read before ad-
ministering the measles-containing vaccine. This op-
tion is the least favored because it will delay receipt of
the measles-containing vaccine.
No data exist for the potential degree of PPD suppression
that might be associated with other parenteral live attenuated
virus vaccines (e.g., varicella or yellow fever). Nevertheless, in
the absence of data, following guidelines for measles-
containing vaccine when scheduling PPD screening and ad-
ministering other parenteral live attenuated virus vaccines
is prudent. If a risk exists that the opportunity to vaccinate
might be missed, vaccination should not be delayed only
because of these theoretical considerations.
Mucosally administered live attenuated virus vaccines (e.g.,
OPV and intranasally administered influenza vaccine) are un-
likely to affect the response to PPD. No evidence has been
reported that inactivated vaccines, polysaccharide vaccines,
recombinant, or subunit vaccines, or toxoids interfere with
response to PPD.
PPD reactivity in the absence of tuberculosis disease is not a
contraindication to administration of any vaccine, including
parenteral live attenuated virus vaccines. Tuberculosis dis-
ease is not a contraindication to vaccination, unless the per-
son is moderately or severely ill. Although no studies have
reported the effect of MMR vaccine on persons with un-
treated tuberculosis, a theoretical basis exists for concern
that measles vaccine might exacerbate tuberculosis (6).
Consequently, before administering MMR to persons with
untreated active tuberculosis, initiating antituberculosis
therapy is advisable (6). Ruling out concurrent immuno-
suppression (e.g., immunosuppression caused by HIV in-
fection) before administering live attenuated vaccines is also
prudent.
Severe Allergy to Vaccine
Components
Vaccine components can cause allergic reactions among cer-
tain recipients. These reactions can be local or systemic and
can include mild to severe anaphylaxis or anaphylactic-like
responses (e.g., generalized urticaria or hives, wheezing, swell-
ing of the mouth and throat, difficulty breathing, hypoten-
sion, and shock). Allergic reactions might be caused by the
vaccine antigen, residual animal protein, antimicrobial agents,
preservatives, stabilizers, or other vaccine components (94).
An extensive listing of vaccine components, their use, and the
vaccines that contain each component has been published (95)
and is also available from CDC’s National Immunization
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Program website at http://www.cdc.gov/nip (accessed Oc-
tober 31, 2001).
The most common animal protein allergen is egg pro-
tein, which is found in vaccines prepared by using embryo-
nated chicken eggs (influenza and yellow fever vaccines).
Ordinarily, persons who are able to eat eggs or egg prod-
ucts safely can receive these vaccines; persons with histories
of anaphylactic or anaphylactic-like allergy to eggs or egg
proteins should not be administered these vaccines. Asking
persons if they can eat eggs without adverse effects is a rea-
sonable way to determine who might be at risk for allergic
reactions from receiving yellow fever and influenza vaccines.
A regimen for administering influenza vaccine to children
with egg hypersensitivity and severe asthma has been de-
veloped (96).
Measles and mumps vaccine viruses are grown in chick
embryo fibroblast tissue culture. Persons with a serious egg
allergy can receive measles- or mumps-containing vaccines
without skin testing or desensitization to egg protein (6). Ru-
bella and varicella vaccines are grown in human diploid cell
cultures and can safely be administered to persons with histo-
ries of severe allergy to eggs or egg proteins. The rare serious
allergic reaction after measles or mumps vaccination or MMR
are not believed to be caused by egg antigens, but to other
components of the vaccine (e.g., gelatin) (97–100). MMR, its
component vaccines, and other vaccines contain hydrolyzed
gelatin as a stabilizer. Extreme caution should be exercised when
administering vaccines that contain gelatin to persons who have
a history of an anaphylactic reaction to gelatin or gelatin-
containing products. Before administering gelatin-
containing vaccines to such persons, skin testing for
sensitivity to gelatin can be considered. However, no spe-
cific protocols for this approach have been published.
 Certain vaccines contain trace amounts of antibiotics or
other preservatives (e.g., neomycin or thimerosal) to which
patients might be severely allergic. The information provided
in the vaccine package insert should be reviewed carefully be-
fore deciding if the rare patient with such allergies should re-
ceive the vaccine. No licensed vaccine contains penicillin or
penicillin derivatives.
Certain vaccines contain trace amounts of neomycin. Per-
sons who have experienced anaphylactic reactions to neomy-
cin should not receive these vaccines. Most often, neomycin
allergy is a contact dermatitis, a manifestation of a delayed
type (cell-mediated) immune response, rather than anaphy-
laxis (101,102). A history of delayed type reactions to neomy-
cin is not a contraindication for administration of these
vaccines.
Thimerosal is an organic mercurial compound in use since
the 1930s and added to certain immunobiologic products as a
preservative. A joint statement issued by the U.S. Public
Health Service and the American Academy of Pediatrics
(AAP) in 1999 (103) and agreed to by the American Acad-
emy of Family Physicians (AAFP) later in 1999, established
the goal of removing thimerosal as soon as possible from
vaccines routinely recommended for infants. Although no
evidence exists of any harm caused by low levels of thimero-
sal in vaccines and the risk was only theoretical (104), this
goal was established as a precautionary measure.
The public is concerned about the health effects of mer-
cury exposure of any type, and the elimination of mercury
from vaccines was judged a feasible means of reducing an
infant’s total exposure to mercury in a world where other
environmental sources of exposure are more difficult or im-
possible to eliminate (e.g., certain foods). Since mid-2001,
vaccines routinely recommended for children have been
manufactured without thimerosal as a preservative and con-
tain either no thimerosal or only trace amounts. Thimero-
sal as a preservative is present in certain other vaccines (e.g.,
Td, DT, one of two adult hepatitis B vaccines, and influ-
enza vaccine). A trace thimerosal formulation of one brand
of influenza vaccine was licensed by FDA in September
2001.
Receiving thimerosal-containing vaccines has been believed
to lead to induction of allergy. However, limited scientific ba-
sis exists for this assertion (94). Hypersensitivity to thimerosal
usually consists of local delayed type hypersensitivity reactions
(105–107). Thimerosal elicits positive delayed type hypersen-
sitivity patch tests in 1%–18% of persons tested, but these
tests have limited or no clinical relevance (108,109). The ma-
jority of patients do not experience reactions to thimerosal
administered as a component of vaccines even when patch or
intradermal tests for thimerosal indicate hypersensitivity (109).
A localized or delayed type hypersensitivity reaction to thime-
rosal is not a contraindication to receipt of a vaccine that con-
tains thimerosal.
Latex Allergy
Latex is liquid sap from the commercial rubber tree. La-
tex contains naturally occurring impurities (e.g., plant pro-
teins and peptides), which are believed to be responsible
for allergic reactions. Latex is processed to form natural rub-
ber latex and dry natural rubber. Dry natural rubber and
natural rubber latex might contain the same plant impuri-
ties as latex but in lesser amounts. Natural rubber latex is
used to produce medical gloves, catheters, and other prod-
ucts. Dry natural rubber is used in syringe plungers, vial
stoppers, and injection ports on intravascular tubing. Syn-
thetic rubber and synthetic latex also are used in medical
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gloves, syringe plungers, and vial stoppers. Synthetic rub-
ber and synthetic latex do not contain natural rubber or
natural latex, and therefore, do not contain the impurities
linked to allergic reactions.
The most common type of latex sensitivity is contact-
type (type 4) allergy, usually as a result of prolonged contact
with latex-containing gloves (110). However, injection-
procedure–associated latex allergies among patients with
diabetes have been described (111–113). Allergic reactions
(including anaphylaxis) after vaccination procedures are rare.
Only one report of an allergic reaction after administering
hepatitis B vaccine in a patient with known severe allergy
(anaphylaxis) to latex has been published (114).
If a person reports a severe (anaphylactic) allergy to latex,
vaccines supplied in vials or syringes that contain natural
rubber should not be administered, unless the benefit of
vaccination outweighs the risk of an allergic reaction to the
vaccine. For latex allergies other than anaphylactic allergies
(e.g., a history of contact allergy to latex gloves), vaccines
supplied in vials or syringes that contain dry natural rub-
ber or natural rubber latex can be administered.
Vaccination of Premature Infants
In the majority of cases, infants born prematurely, re-
gardless of birth weight, should be vaccinated at the same
chronological age and according to the same schedule and
precautions as full-term infants and children. Birth weight
and size are not factors in deciding whether to postpone
routine vaccination of a clinically stable premature infant
(115–117), except for hepatitis B vaccine. The full recom-
mended dose of each vaccine should be used. Divided or
reduced doses are not recommended (118).
Studies demonstrate that decreased seroconversion rates
might occur among certain premature infants with low birth
weights (i.e., <2,000 grams) after administration of hepatitis
B vaccine at birth (119). However, by chronological age 1
month, all premature infants, regardless of initial birth weight
or gestational age are as likely to respond as adequately as older
and larger infants (120–122). A premature infant born to
HBsAg-positive mothers and mothers with unknown
HBsAg status must receive immunoprophylaxis with hepa-
titis B vaccine and hepatitis B immunoglobulin (HBIG)
<12 hours after birth. If these infants weigh <2,000 grams
at birth, the initial vaccine dose should not be counted to-
wards completion of the hepatitis B vaccine series, and three
additional doses of hepatitis B vaccine should be adminis-
tered, beginning when the infant is age 1 month. The opti-
mal timing of the first dose of hepatitis B vaccine for
premature infants of HBsAg-negative mothers with a birth
weight of <2,000 grams has not been determined. How-
ever, these infants can receive the first dose of the hepatitis
B vaccine series at chronological age 1 month. Premature
infants discharged from the hospital before chronological
age 1 month can also be administered hepatitis B vaccine at
discharge, if they are medically stable and have gained weight
consistently.
Breast-Feeding and Vaccination
Neither inactivated nor live vaccines administered to a lac-
tating woman affect the safety of breast-feeding for mothers
or infants. Breast-feeding does not adversely affect immuniza-
tion and is not a contraindication for any vaccine. Limited
data indicate that breast-feeding can enhance the response
to certain vaccine antigens (123). Breast-fed infants should
be vaccinated according to routine recommended sched-
ules (124–126).
Although live vaccines multiply within the mother’s body,
the majority have not been demonstrated to be excreted in
human milk. Although rubella vaccine virus might be excreted
in human milk, the virus usually does not infect the infant. If
infection does occur, it is well-tolerated because the viruses are
attenuated (127). Inactivated, recombinant, subunit, polysac-
charide, conjugate vaccines and toxoids pose no risk for mothers
who are breast-feeding or for their infants.
Vaccination During Pregnancy
Risk to a developing fetus from vaccination of the mother
during pregnancy is primarily theoretical. No evidence exists
of risk from vaccinating pregnant women with inactivated vi-
rus or bacterial vaccines or toxoids (128,129). Benefits of vac-
cinating pregnant women usually outweigh potential risks
when the likelihood of disease exposure is high, when in-
fection would pose a risk to the mother or fetus, and when
the vaccine is unlikely to cause harm.
Td toxoid is indicated routinely for pregnant women. Pre-
viously vaccinated pregnant women who have not received a
Td vaccination within the last 10 years should receive a booster
dose. Pregnant women who are not immunized or only par-
tially immunized against tetanus should complete the primary
series (130). Depending on when a woman seeks prenatal care
and the required interval between doses, one or two doses of
Td can be administered before delivery. Women for whom
the vaccine is indicated, but who have not completed the rec-
ommended three-dose series during pregnancy, should receive
follow-up after delivery to ensure the series is completed.
Women in the second and third trimesters of pregnancy have
been demonstrated to be at increased risk for hospitalization
from influenza (131). Therefore, routine influenza vaccina-
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tion is recommended for healthy women who will be be-
yond the first trimester of pregnancy (i.e., >14 weeks of
gestation) during influenza season (usually December–
March in the United States) (88). Women who have medi-
cal conditions that increase their risk for complications of
influenza should be vaccinated before the influenza season,
regardless of the stage of pregnancy.
IPV can be administered to pregnant women who are at
risk for exposure to wild-type poliovirus infection (4). Hepa-
titis B vaccine is recommended for pregnant women at risk
for hepatitis B virus infection (132). Hepatitis A, pneumo-
coccal polysaccharide, and meningococcal polysaccharide
vaccines should be considered for women at increased risk
for those infections (43,133,134).
Pregnant women who must travel to areas where the risk
for yellow fever is high should receive yellow fever vaccine,
because the limited theoretical risk from vaccination is sub-
stantially outweighed by the risk for yellow fever infection
(22,135). Pregnancy is a contraindication for measles,
mumps, rubella, and varicella vaccines. Although of theo-
retical concern, no cases of congenital rubella or varicella
syndrome or abnormalities attributable to fetal infection
have been observed among infants born to susceptible
women who received rubella or varicella vaccines during
pregnancy (6,136). Because of the importance of protect-
ing women of childbearing age against rubella, reasonable
practices in any immunization program include asking
women if they are pregnant or intend to become pregnant
in the next 4 weeks, not vaccinating women who state that
they are pregnant, explaining the potential risk for the fe-
tus to women who state that they are not pregnant, and
counseling women who are vaccinated not to become preg-
nant during the 4 weeks after MMR vaccination (6,35,137).
Routine pregnancy testing of women of childbearing age
before administering a live-virus vaccine is not recommended
(6). If a pregnant woman is inadvertently vaccinated or if
she becomes pregnant within 4 weeks after MMR or vari-
cella vaccination, she should be counseled regarding the
theoretical basis of concern for the fetus; however, MMR or
varicella vaccination during pregnancy should not ordinarily
be a reason to terminate pregnancy (6,8).
Persons who receive MMR vaccine do not transmit the vac-
cine viruses to contacts (6). Transmission of varicella vaccine
virus to contacts is rare (138). MMR and varicella vaccines
should be administered when indicated to the children and
other household contacts of pregnant women (6,8).
All pregnant women should be evaluated for immunity to
rubella and be tested for the presence of HBsAg (6,35,132).
Women susceptible to rubella should be vaccinated immedi-
ately after delivery. A woman known to be HBsAg-positive
should be followed carefully to ensure that the infant re-
ceives HBIG and begins the hepatitis B vaccine series <12
hours after birth and that the infant completes the recom-
mended hepatitis B vaccine series (132). No known risk
exists for the fetus from passive immunization of pregnant
women with immune globulin preparations.
Vaccination of Internationally
Adopted Children
The ability of a clinician to determine that a person is
protected on the basis of their country of origin and their
records alone is limited. Internationally adopted children
should receive vaccines according to recommended sched-
ules for children in the United States. Only written docu-
mentation should be accepted as evidence of prior
vaccination. Written records are more likely to predict pro-
tection if the vaccines, dates of administration, intervals
between doses, and the child’s age at the time of immuni-
zation are comparable to the current U.S. recommenda-
tions. Although vaccines with inadequate potency have been
produced in other countries (139,140), the majority of vac-
cines used worldwide are produced with adequate quality
control standards and are potent.
The number of American families adopting children from
outside the United States has increased substantially in recent
years (141). Adopted children’s birth countries often have im-
munization schedules that differ from the recommended child-
hood immunization schedule in the United States. Differences
in the U.S. immunization schedule and those used in other
countries include the vaccines administered, the recommended
ages of administration, and the number and timing of doses.
Data are inconclusive regarding the extent to which an
internationally adopted child’s immunization record reflects
the child’s protection. A child’s record might indicate ad-
ministration of MMR vaccine when only single-antigen
measles vaccine was administered. A study of children
adopted from the People’s Republic of China, Russia, and
Eastern Europe determined that only 39% (range: 17%–
88% by country) of children with documentation of >3
doses of DTP before adoption had protective levels of diph-
theria and tetanus antitoxin (142). However, antibody test-
ing was performed by using a hemagglutination assay, which
tends to underestimate protection and cannot directly be
compared with antibody concentration (143). Another
study measured antibody to diphtheria and tetanus toxins
among 51 children who had records of having received >2
doses of DTP. The majority of the children were from Rus-
sia, Eastern Europe, and Asian countries, and 78% had re-
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ceived all their vaccine doses in an orphanage. Overall, 94%
had evidence of protection against diphtheria (EIA > 0.1
IU/mL). A total of 84% had protection against tetanus (en-
zyme-linked immunosorbent assay [ELISA] > 0.5 IU/mL).
Among children without protective tetanus antitoxin con-
centration, all except one had records of >3 doses of vac-
cine, and the majority of nonprotective concentrations were
categorized as indeterminate (ELISA = 0.05–0.49 IU/mL)
(144). Reasons for the discrepant findings in these two stud-
ies probably relate to different laboratory methodologies;
the study using a hemagglutination assay might have un-
derestimated the number of children who were protected.
Additional studies using standardized methodologies are
needed. Data are likely to remain limited for countries other
than the People’s Republic of China, Russia, and Eastern
Europe because of the limited number of adoptees from
other countries.
Physicians and other health-care providers can follow one
of multiple approaches if a question exists regarding whether
vaccines administered to an international adoptee were im-
munogenic. Repeating the vaccinations is an acceptable op-
tion. Doing so is usually safe and avoids the need to obtain
and interpret serologic tests. If avoiding unnecessary injec-
tions is desired, judicious use of serologic testing might be
helpful in determining which immunizations are needed.
This report provides guidance on possible approaches to
evaluation and revaccination for each vaccine recommended
universally for children in the United States (see Table 6
and the following sections).
MMR Vaccine
The simplest approach to resolving concerns regarding
MMR immunization among internationally adopted chil-
dren is to revaccinate with one or two doses of MMR vac-
cine, depending on the child’s age. Serious adverse events
after MMR vaccinations are rare (6). No evidence indicates
that administering MMR vaccine increases the risk for ad-
verse reactions among persons who are already immune to
measles, mumps, or rubella as a result of previous vaccina-
tion or natural disease. Doses of measles-containing vaccine
Measles, mumps, and rubella (MMR)
Haemophilus influenzae type b (Hib)
Hepatitis B
Poliovirus
Diphtheria and tetanus toxoids and acellular
pertussis (DTaP)
Varicella
Pneumococcal
Revaccinate with MMR
Age-appropriate revaccination
Serological testing for hepatitis B
surface antigen
Revaccinate with inactivated poliovirus
vaccine (IPV)
Revaccination with DTaP, with serologic
testing for specific IgG antibody to tetanus
and diphtheria toxins in the event of a
severe local reaction
Age-appropriate vaccination of children who
lack a reliable history of previous varicella
disease
Age-appropriate vaccination
Serologic testing for immunoglobulin G (IgG)
antibody to vaccine viruses indicated by
vaccination record
—
—
Serologic testing for neutralizing antibody to
poliovirus types 1, 2, and 3 (limited availability),
or administer single dose of IPV, followed by
serologic testing for neutralizing antibody to
poliovirus types 1, 2, and 3
Children whose records indicate receipt of >3
doses: serologic testing for specific IgG antibody
to diphtheria and tetanus toxins before adminis-
tering additional doses (see text), or administer
a single booster dose of DTaP, followed by
serological testing after 1 month for specific IgG
antibody to diphtheria and tetanus toxins with
revaccination as appropriate (see text)
—
—
TABLE 6. Approaches to the evaluation and vaccination of internationally adopted children
Vaccine Recommended approach Alternative approach
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administered before the first birthday should not be counted
as part of the series (6). Alternatively, serologic testing for
immunoglobulin G (IgG) antibody to vaccine viruses indi-
cated on the vaccination record can be considered. Sero-
logic testing is widely available for measles and rubella IgG
antibody. A child whose record indicates receipt of monova-
lent measles or measles-rubella vaccine at age >1 year and
who has protective antibody against measles and rubella
should receive a single dose of MMR as age-appropriate to
ensure protection against mumps (and rubella if measles
vaccine alone had been used). If a child whose record indi-
cates receipt of MMR at age >12 months has a protective
concentration of antibody to measles, no additional vacci-
nation is needed unless required for school entry.
Hib Vaccine
Serologic correlates of protection for children vaccinated
>2 months previously might be difficult to interpret. Be-
cause the number of vaccinations needed for protection
decreases with age and adverse events are rare (24), age-
appropriate vaccination should be provided. Hib vaccination
is not recommended routinely for children aged >5 years.
Hepatitis B Vaccine
Serologic testing for HBsAg is recommended for interna-
tional adoptees, and children determined to be HBsAg-
positive should be monitored for the development of liver
disease. Household members of HBsAg-positive children
should be vaccinated. A child whose records indicate re-
ceipt of >3 doses of vaccine can be considered protected,
and additional doses are not needed if >1 doses were ad-
ministered at age >6 months. Children who received their
last hepatitis B vaccine dose at age <6 months should re-
ceive an additional dose at age >6 months. Those who have
received <3 doses should complete the series at the recom-
mended intervals and ages (Table 1).
Poliovirus Vaccine
The simplest approach is to revaccinate internationally
adopted children with IPV according to the U.S. schedule.
Adverse events after IPV are rare (4). Children appropri-
ately vaccinated with three doses of OPV in economically
developing countries might have suboptimal seroconversion,
including to type 3 poliovirus (125). Serologic testing for
neutralizing antibody to poliovirus types 1, 2, and 3 can be
obtained commercially and at certain state health depart-
ment laboratories. Children with protective titers against
all three types do not need revaccination and should com-
plete the schedule as age-appropriate. Alternately, because
the booster response after a single dose of IPV is excellent
among children who previously received OPV (3), a single
dose of IPV can be administered initially with serologic
testing performed 1 month later.
DTaP Vaccine
Vaccination providers can revaccinate a child with DTaP
vaccine without regard to recorded doses; however, one con-
cern regarding this approach is that data indicate increased
rates of local adverse reactions after the fourth and fifth doses
of DTP or DTaP (42). If a revaccination approach is adopted
and a severe local reaction occurs, serologic testing for spe-
cific IgG antibody to tetanus and diphtheria toxins can be
measured before administering additional doses. Protective
concentration** indicates that further doses are unneces-
sary and subsequent vaccination should occur as age-
appropriate. No established serologic correlates exist for
protection against pertussis.
For a child whose record indicates receipt of >3 doses of
DTP or DTaP, serologic testing for specific IgG antibody to
both diphtheria and tetanus toxin before additional doses
is a reasonable approach. If a protective concentration is
present, recorded doses can be considered valid, and the
vaccination series should be completed as age-appropriate.
Indeterminate antibody concentration might indicate im-
munologic memory but antibody waning; serology can be
repeated after a booster dose if the vaccination provider
wishes to avoid revaccination with a complete series.
Alternately, for a child whose records indicate receipt of
>3 doses, a single booster dose can be administered, fol-
lowed by serologic testing after 1 month for specific IgG
antibody to both diphtheria and tetanus toxins. If a pro-
tective concentration is obtained, the recorded doses can
be considered valid and the vaccination series completed as
age-appropriate. Children with indeterminate concentra-
tion after a booster dose should be revaccinated with a com-
plete series.
Varicella Vaccine
Varicella vaccine is not administered in the majority of
countries. A child who lacks a reliable medical history re-
garding prior varicella disease should be vaccinated as age-
appropriate (8).
Pneumococcal Vaccines
Pneumococcal conjugate and pneumococcal polysaccha-
ride vaccines are not administered in the majority of coun-
**Toxin neutralization testing is reliable but not readily available. Enzyme
immunoassay tests are the most readily available, although passive
hemagglutination is available in certain areas. Physicians should contact the
laboratory performing the test for interpretive standards and limitations. Protective
concentrations for diphtheria are defined as >0.1 IU/mL and for tetanus as
>0.1–0.2 IU/mL.
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tries and should be administered as age-appropriate or as
indicated by the presence of underlying medical conditions
(26,43).
Altered Immunocompetence
ACIP’s statement regarding vaccinating immuno-
compromised persons summarizes recommendations regard-
ing the efficacy, safety, and use of specific vaccines and
immune globulin preparations for immunocompromised
persons (145). ACIP statements regarding individual vac-
cines or immune globulins contain additional information
regarding those concerns.
Severe immunosuppression can be the result of congeni-
tal immunodeficiency, HIV infection, leukemia, lymphoma,
generalized malignancy or therapy with alkylating agents,
antimetabolites, radiation, or a high dose, prolonged course
of corticosteroids. The degree to which a person is
immunocompromised should be determined by a physi-
cian. Severe complications have followed vaccination with
live-virus vaccines and live bacterial vaccines among
immunocompromised patients (146–153). These patients
should not receive live vaccines except in certain circum-
stances that are noted in the following paragraphs. MMR
vaccine viruses are not transmitted to contacts, and trans-
mission of varicella vaccine virus is rare (6,138). MMR and
varicella vaccines should be administered to susceptible
household and other close contacts of immunocompromised
patients when indicated.
Persons with HIV infection are at increased risk for severe
complications if infected with measles. No severe or un-
usual adverse events have been reported after measles vacci-
nation among HIV-infected persons who did not have
evidence of severe immunosuppression (154–157). As a
result, MMR vaccination is recommended for all HIV-
infected persons who do not have evidence of severe immu-
nosuppression†† and for whom measles vaccination would
otherwise be indicated.
Children with HIV infection are at increased risk for com-
plications of primary varicella and for herpes zoster, com-
pared with immunocompetent children (138,158). Limited
data among asymptomatic or mildly symptomatic HIV-
infected children (CDC class N1 or A1, age-specific CD4+
lymphocyte percentages of >25%) indicate that varicella
vaccine is immunogenic, effective, and safe (138,159). Va-
ricella vaccine should be considered for asymptomatic or
mildly symptomatic HIV-infected children in CDC class
N1 or A1 with age-specific CD4+ T lymphocyte percent-
ages of >25%. Eligible children should receive two doses of
varicella vaccine with a 3-month interval between doses
(138).
HIV-infected persons who are receiving regular doses of
IGIV might not respond to varicella vaccine or MMR or its
individual component vaccines because of the continued
presence of passively acquired antibody. However, because
of the potential benefit, measles vaccination should be con-
sidered approximately 2 weeks before the next scheduled
dose of IGIV (if not otherwise contraindicated), although
an optimal immune response is unlikely to occur. Unless
serologic testing indicates that specific antibodies have been
produced, vaccination should be repeated (if not otherwise
contraindicated) after the recommended interval (Table 4).
An additional dose of IGIV should be considered for per-
sons on maintenance IGIV therapy who are exposed to
measles >3 weeks after administering a standard dose (100–
400 mg/kg body weight) of IGIV.
Persons with cellular immunodeficiency should not re-
ceive varicella vaccine. However, ACIP recommends that
persons with impaired humoral immunity (e.g.,
hypogammaglobulinemia or dysgammaglobulinemia)
should be vaccinated (138,160).
Inactivated, recombinant, subunit, polysaccharide, and
conjugate vaccines and toxoids can be administered to all
immunocompromised patients, although response to such
vaccines might be suboptimal. If indicated, all inactivated
vaccines are recommended for immunocompromised per-
sons in usual doses and schedules. In addition, pneumo-
coccal, meningococcal, and Hib vaccines are recommended
specifically for certain groups of immunocompromised pa-
tients, including those with functional or anatomic asplenia
(145,161).
Except for influenza vaccine, which should be adminis-
tered annually (88), vaccination during chemotherapy or
radiation therapy should be avoided because antibody re-
sponse is suboptimal. Patients vaccinated while receiving
immunosuppressive therapy or in the 2 weeks before start-
ing therapy should be considered unimmunized and should
be revaccinated >3 months after therapy is discontinued.
Patients with leukemia in remission whose chemotherapy
has been terminated for >3 months can receive live-virus
vaccines.
†† As defined by a low age-specific total CD4+ T lymphocyte count or a low CD4+
T lymphocyte count as a percentage of total lymphocytes. ACIP recommendations
for using MMR vaccine contain additional details regarding the criteria for
severe immunosuppression in persons with HIV infection (Source: CDC.
Measles, mumps, and rubella — vaccine use and strategies for elimination of
measles, rubella, and congenital rubella syndrome and control of mumps:
recommendations of the Advisory Committee on Immunization Practices [ACIP].
MMWR 1998;47[No. RR-8]:1–57).
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Corticosteroids
The exact amount of systemically absorbed corticoster-
oids and the duration of administration needed to suppress
the immune system of an otherwise immunocompetent
person are not well-defined. The majority of experts agree
that corticosteroid therapy usually is not a contraindica-
tion to administering live-virus vaccine when it is short-
term (i.e., <2 weeks); a low to moderate dose; long-term,
alternate-day treatment with short-acting preparations;
maintenance physiologic doses (replacement therapy); or
administered topically (skin or eyes) or by intra-articular,
bursal, or tendon injection (145). Although of theoretical
concern, no evidence of increased severity of reactions to
live vaccines has been reported among persons receiving
corticosteroid therapy by aerosol, and such therapy is not a
reason to delay vaccination. The immunosuppressive effects
of steroid treatment vary, but the majority of clinicians con-
sider a dose equivalent to either >2 mg/kg of body weight
or a total of 20 mg/day of prednisone or equivalent for chil-
dren who weigh >10 kg, when administered for >2 weeks
as sufficiently immunosuppressive to raise concern regard-
ing the safety of vaccination with live-virus vaccines
(84,145). Corticosteroids used in greater than physiologic
doses also can reduce the immune response to vaccines.
Vaccination providers should wait >1 month after discon-
tinuation of therapy before administering a live-virus vac-
cine to patients who have received high systemically
absorbed doses of corticosteroids for >2 weeks.
Vaccination of Hematopoietic
Stem Cell Transplant Recipients
Hematopoietic stem cell transplant (HSCT) is the infu-
sion of hematopoietic stem cells from a donor into a patient
who has received chemotherapy and often radiation, both
of which are usually bone marrow ablative. HSCT is used
to treat a variety of neoplastic diseases, hematologic disor-
ders, immunodeficiency syndromes, congenital enzyme
deficiencies, and autoimmune disorders. HSCT recipients
can receive either their own cells (i.e., autologous HSCT)
or cells from a donor other than the transplant recipient
(i.e., allogeneic HSCT). The source of the transplanted stem
cells can be from either a donor’s bone marrow or periph-
eral blood or harvested from the umbilical cord of a new-
born infant (162).
Antibody titers to vaccine-preventable diseases (e.g., teta-
nus, poliovirus, measles, mumps, rubella, and encapsulated
bacteria) decline during the 1–4 years after allogeneic or au-
tologous HSCT if the recipient is not revaccinated (163–167).
HSCT recipients are at increased risk for certain vaccine-pre-
ventable diseases, including those caused by encapsulated
bacteria (i.e., pneumococcal and Hib infections). As a re-
sult, HSCT recipients should be routinely revaccinated af-
ter HSCT, regardless of the source of the transplanted stem
cells. Revaccination with inactivated, recombinant, subunit,
polysaccharide, and Hib vaccines should begin 12 months
after HSCT (162). An exception to this recommendation
is for influenza vaccine, which should be administered at
>6 months after HSCT and annually for the life of the re-
cipient thereafter. MMR vaccine should be administered
24 months after transplantation if the HSCT recipient is
presumed to be immunocompetent. Varicella, meningo-
coccal, and pneumococcal conjugate vaccines are not rec-
ommended for HSCT recipients because of insufficient
experience using these vaccines among HSCT recipients
(162). The household and other close contacts of HSCT
recipients and health-care workers who care for HSCT re-
cipients, should be appropriately vaccinated, including
against influenza, measles, and varicella. Additional details
of vaccination of HSCT recipients and their contacts can
be found in a specific CDC report on this topic (162).
Vaccinating Persons with Bleeding
Disorders and Persons Receiving
Anticoagulant Therapy
Persons with bleeding disorders (e.g., hemophilia) and
persons receiving anticoagulant therapy have an increased
risk for acquiring hepatitis B and at least the same risk as
the general population of acquiring other vaccine-
preventable diseases. However, because of the risk for he-
matoma formation after injections, intramuscular injections
are often avoided among persons with bleeding disorders
by using the subcutaneous or intradermal routes for vac-
cines that are administered normally by the intramuscular
route. Hepatitis B vaccine administered intramuscularly to
153 persons with hemophilia by using a 23-gauge needle,
followed by steady pressure to the site for 1–2 minutes,
resulted in a 4% bruising rate with no patients requiring
factor supplementation (168). Whether antigens that pro-
duce more local reactions (e.g., pertussis) would produce
an equally low rate of bruising is unknown.
When hepatitis B or any other intramuscular vaccine is
indicated for a patient with a bleeding disorder or a person
receiving anticoagulant therapy, the vaccine should be ad-
ministered intramuscularly if, in the opinion of a physician
familiar with the patient’s bleeding risk, the vaccine can be
administered with reasonable safety by this route. If the
patient receives antihemophilia or similar therapy, intra-
muscular vaccinations can be scheduled shortly after such
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therapy is administered. A fine needle (<23 gauge) should
be used for the vaccination and firm pressure applied to the
site, without rubbing, for >2 minutes. The patient or fam-
ily should be instructed concerning the risk for hematoma
from the injection.
Vaccination Records
Consent to Vaccinate
The National Childhood Vaccine Injury Act of 1986 (42
U.S.C. § 300aa-26) requires that all health-care providers
in the United States who administer any vaccine covered by
the act§§ must provide a copy of the relevant, current edi-
tion of the vaccine information materials that have been
produced by CDC before administering each dose of the
vaccine. The vaccine information material must be provided
to the parent or legal representative of any child or to any
adult to whom the physician or other health-care provider
intends to administer the vaccine. The Act does not require
that a signature be obtained, but documentation of con-
sent is recommended or required by certain state or local
authorities.
Provider Records
Documentation of patient vaccinations helps ensure that
persons in need of a vaccine receive it and that adequately
vaccinated patients are not overimmunized, possibly increas-
ing the risk for local adverse events (e.g., tetanus toxoid).
Serologic test results for vaccine-preventable diseases (e.g.,
those for rubella screening) as well as documented episodes
of adverse events also should be recorded in the permanent
medical record of the vaccine recipient.
Health-care providers who administer vaccines covered
by the National Childhood Vaccine Injury Act are required
to ensure that the permanent medical record of the recipi-
ent (or a permanent office log or file) indicates the date the
vaccine was administered, the vaccine manufacturer, the
vaccine lot number, and the name, address, and title of the
person administering the vaccine. Additionally, the provider
is required to record the edition date of the vaccine infor-
mation materials distributed and the date those materials
were provided. Regarding this Act, the term health-care pro-
vider is defined as any licensed health-care professional, or-
ganization, or institution, whether private or public
(including federal, state, and local departments and agen-
cies), under whose authority a specified vaccine is adminis-
tered. ACIP recommends that this same information be
kept for all vaccines, not just for those required by the Na-
tional Childhood Vaccine Injury Act.
Patients’ Personal Records
Official immunization cards have been adopted by every
state, territory, and the District of Columbia to encourage
uniformity of records and to facilitate assessment of immu-
nization status by schools and child care centers. The records
also are key tools in immunization education programs aimed
at increasing parental and patient awareness of the need for
vaccines. A permanent immunization record card should
be established for each newborn infant and maintained by
the parent or guardian. In certain states, these cards are
distributed to new mothers before discharge from the hos-
pital. Using immunization record cards for adolescents and
adults also is encouraged.
Registries
Immunization registries are confidential, population-
based, computerized information systems that collect vac-
cination data for as many children as possible within a
geographic area. Registries are a critical tool that can in-
crease and sustain increased vaccination coverage by con-
solidating vaccination records of children from multiple
providers, generating reminder and recall vaccination no-
tices for each child, and providing official vaccination forms
and vaccination coverage assessments (169). A fully opera-
tional immunization registry also can prevent duplicate vac-
cinations, limit missed appointments, reduce vaccine waste,
and reduce staff time required to produce or locate immu-
nization records or certificates. The National Vaccine Advi-
sory Committee strongly encourages development of
community- or state-based immunization registry systems
and recommends that vaccination providers participate in
these registries whenever possible (170,171). A 95% par-
ticipation of children aged <6 years in fully operational
population-based immunization registries is a national
health objective for 2010 (172).
Reporting Adverse Events
After Vaccination
Modern vaccines are safe and effective; however, adverse
events have been reported after administration of all vaccines
(82). These events range from frequent, minor, local reactions
to extremely rare, severe, systemic illness (e.g., encephalopa-
thy). Establishing evidence for cause-and-effect relationships
on the basis of case reports and case series alone is impos-
§ §As of January 2002, vaccines covered by the act include diphtheria, tetanus,
pertussis, measles, mumps, rubella, poliovirus, hepatitis B, Hib, varicella, and
pneumococcal conjugate.
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sible because temporal association alone does not necessar-
ily indicate causation. Unless the syndrome that occurs af-
ter vaccination is clinically or pathologically distinctive, more
detailed epidemiologic studies to compare the incidence of
the event among vaccinees with the incidence among un-
vaccinated persons are often necessary. Reporting adverse
events to public health authorities, including serious events,
is a key stimulus to developing studies to confirm or refute
a causal association with vaccination. More complete infor-
mation regarding adverse reactions to a specific vaccine can
be found in the ACIP recommendations for that vaccine
and in a specific statement on vaccine adverse reactions (82).
The National Childhood Vaccine Injury Act requires
health-care providers to report selected events occurring af-
ter vaccination to the Vaccine Adverse Event Reporting Sys-
tem (VAERS). Events for which reporting is required appear
in the Vaccine Injury Table.¶¶ Persons other than health-
care workers also can report adverse events to VAERS. Ad-
verse events other than those that must be reported or that
occur after administration of vaccines not covered by the
act, including events that are serious or unusual, also should
be reported to VAERS, even if the physician or other health-
care provider is uncertain they are related causally. VAERS
forms and instructions are available in the FDA Drug Bul-
letin, by calling the 24-hour VAERS Hotline at 800-822-
7967, or from the VAERS website at http://www.vaers.org
(accessed November 7, 2001).
Vaccine Injury Compensation Program
The National Vaccine Injury Compensation Program, es-
tablished by the National Childhood Vaccine Injury Act, is a
no-fault system in which persons thought to have suffered an
injury or death as a result of administration of a covered vac-
cine can seek compensation. The program, which became op-
erational on October 1, 1988, is intended as an alternative to
civil litigation under the traditional tort system in that negli-
gence need not be proven. Claims arising from covered vac-
cines must first be adjudicated through the program before
civil litigation can be pursued.
The program relies on a Vaccine Injury Table listing the vac-
cines covered by the program as well as the injuries, disabili-
ties, illnesses, and conditions (including death) for which
compensation might be awarded. The table defines the time
during which the first symptom or substantial aggravation of
an injury must appear after vaccination. Successful claimants
receive a legal presumption of causation if a condition listed in
the table is proven, thus avoiding the need to prove actual
causation in an individual case. Claimants also can prevail for
conditions not listed in the table if they prove causation. Inju-
ries after administration of vaccines not listed in the legisla-
tion authorizing the program are not eligible for
compensation through the program. Additional informa-
tion is available from the following:
National Vaccine Injury Compensation Program
Health Resources and Services Administration
Parklawn Building, Room 8-46
5600 Fishers Lane
Rockville, MD 20857
Telephone: 800-338-2382 (24-hour recording)
Internet: http:// www.hrsa.gov/bhpr/vicp (accessed
November 7, 2001)
Persons wishing to file a claim for vaccine injury should
call or write the following:
U.S. Court of Federal Claims
717 Madison Place, N.W.
Washington, D.C. 20005
Telephone: 202-219-9657
Benefit and Risk Communication
Parents, guardians, legal representatives, and adolescent
and adult patients should be informed regarding the ben-
efits and risks of vaccines in understandable language. Op-
portunity for questions should be provided before each
vaccination. Discussion of the benefits and risks of vaccina-
tion is sound medical practice and is required by law.
The National Childhood Vaccine Injury Act requires that
vaccine information materials be developed for each vaccine
covered by the Act. These materials, known as Vaccine In-
formation Statements, must be provided by all public and
private vaccination providers each time a vaccine is admin-
istered. Copies of Vaccine Information Statements are avail-
able from state health authorities responsible for
immunization, or they can be obtained from CDC’s Na-
tional Immunization Program website at http://
www.cdc.gov/nip (accessed November 7, 2001). Transla-
tions of Vaccine Information Statements into languages other
than English are available from certain state immunization
programs and from the Immunization Action Coalition
website at http://www.immunize.org (accessed November 7,
2001).
Health-care providers should anticipate that certain par-
ents or patients will question the need for or safety of vacci-
nation, refuse certain vaccines, or even reject all vaccinations.
A limited number of persons might have religious or per-
sonal objections to vaccinations. Others wish to enter into
¶ ¶The Vaccine Injury Table can be obtained from the Vaccine Injury Compensation
Program Internet site at <http://www.hrsa.dhhs.gov/bhpr/vicp/table.htm>
(accessed November 7, 2001).
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a dialogue regarding the risks and benefits of certain vac-
cines. Having a basic understanding of how patients view
vaccine risk and developing effective approaches in dealing
with vaccine safety concerns when they arise is imperative
for vaccination providers.
Each person understands and reacts to vaccine informa-
tion on the basis of different factors, including prior experi-
ence, education, personal values, method of data
presentation, perceptions of the risk for disease, perceived
ability to control those risks, and their risk preference. In-
creasingly, through the media and nonauthoritative Internet
sites, decisions regarding risk are based on inaccurate infor-
mation. Only through direct dialogue with parents and by
using available resources, health-care professionals can pre-
vent acceptance of media reports and information from
nonauthoritative Internet sites as scientific fact.
When a parent or patient initiates discussion regarding a
vaccine controversy, the health-care professional should dis-
cuss the specific concerns and provide factual information,
using language that is appropriate. Effective, empathetic
vaccine risk communication is essential in responding to
misinformation and concerns, although recognizing that for
certain persons, risk assessment and decision-making is dif-
ficult and confusing. Certain vaccines might be acceptable
to the resistant parent. Their concerns should then be ad-
dressed in the context of this information, using the Vac-
cine Information Statements and offering other resource
materials (e.g., information available on the National Im-
munization Program website).
Although a limited number of providers might choose to
exclude from their practice those patients who question or
refuse vaccination, the more effective public health strategy
is to identify common ground and discuss measures that
need to be followed if the patient’s decision is to defer vac-
cination. Health-care providers can reinforce key points re-
garding each vaccine, including safety, and emphasize risks
encountered by unimmunized children. Parents should be
advised of state laws pertaining to school or child care en-
try, which might require that unimmunized children stay
home from school during outbreaks. Documentation of these
discussions in the patient’s record, including the refusal to
receive certain vaccines (i.e., informed refusal), might re-
duce any potential liability if a vaccine-preventable disease
occurs in the unimmunized patient.
Vaccination Programs
The best way to reduce vaccine-preventable diseases is to
have a highly immune population. Universal vaccination is
a critical part of quality health care and should be accom-
plished through routine and intensive vaccination programs
implemented in physicians’ offices and in public health clin-
ics. Programs should be established and maintained in all
communities to ensure vaccination of all children at the
recommended age. In addition, appropriate vaccinations
should be available for all adolescents and adults.
Physicians and other pediatric vaccination providers
should adhere to the standards for child and adolescent im-
munization practices (1). These standards define appropri-
ate vaccination practices for both the public and private
sectors. The standards provide guidance on practices that
will result in eliminating barriers to vaccination. These in-
clude practices aimed at eliminating unnecessary prerequi-
sites for receiving vaccinations, eliminating missed
opportunities to vaccinate, improving procedures to assess
vaccination needs, enhancing knowledge regarding vacci-
nations among parents and providers, and improving the
management and reporting of adverse events. Additionally,
the standards address the importance of recall and reminder
systems and using assessments to monitor clinic or office
vaccination coverage levels among patients.
Standards of practice also have been published to increase
vaccination coverage among adults (2). Persons aged >65
years and all adults with medical conditions that place them
at risk for pneumococcal disease should receive >1 doses of
pneumococcal polysaccharide vaccine. All persons aged >50
years and those with medical conditions that increase the
risk for complications from influenza should receive annual
influenza vaccination. All adults should complete a primary
series of tetanus and diphtheria toxoids and receive a booster
dose every 10 years. Adult vaccination programs also should
provide MMR and varicella vaccines whenever possible to
anyone susceptible to measles, mumps, rubella, or varicella.
Persons born after 1956 who are attending college (or other
posthigh school educational institutions), who are employed
in environments that place them at increased risk for measles
transmission (e.g., health-care facilities), or who are travel-
ing to areas with endemic measles, should have documen-
tation of having received two doses of MMR on or after
their first birthday or other evidence of immunity (6,173).
All other adults born after 1956 should have documenta-
tion of >1 doses of MMR vaccine on or after their first birth-
day or have other evidence of immunity. No evidence
indicates that administering MMR vaccine increases the
risk for adverse reactions among persons who are already
immune to measles, mumps, or rubella as a result of previ-
ous vaccination or disease. Widespread use of hepatitis B
vaccine is encouraged for all persons who might be at in-
Vol. 51 / RR-2 Recommendations and Reports 27
creased risk (e.g., adolescents and adults who are either in a
group at high risk or reside in areas with increased rates of
injection-drug use, teenage pregnancy, or sexually trans-
mitted disease).
Every visit to a physician or other health-care provider
can be an opportunity to update a patient’s immunization
status with needed vaccinations. Official health agencies
should take necessary steps, including developing and en-
forcing school immunization requirements, to ensure that
students at all grade levels (including college) and those in
child care centers are protected against vaccine-preventable
diseases. Agencies also should encourage institutions (e.g.,
hospitals and long-term care facilities) to adopt policies re-
garding the appropriate vaccination of patients, residents,
and employees (173).
Dates of vaccination (day, month, and year) should be
recorded on institutional immunization records (e.g., those
kept in schools and child care centers). This record will
facilitate assessments that a primary vaccination series has
been completed according to an appropriate schedule and
that needed booster doses have been administered at the
appropriate time.
The independent, nonfederal Task Force on Community
Preventive Services (the Task Force) gives public health
decision-makers recommendations on population-based in-
terventions to promote health and prevent disease, injury,
disability, and premature death. The recommendations are
based on systematic reviews of the scientific literature re-
garding effectiveness and cost-effectiveness of these inter-
ventions. In addition, the Task Force identifies critical
information regarding the other effects of these interven-
tions, as well as the applicability to specific populations
and settings and the potential barriers to implementation.
This information is available through the Internet at
http://www.thecommunityguide.org (accessed November 7,
2001).
Beginning in 1996, the Task Force systematically reviewed
published evidence on the effectiveness and cost-effectiveness
of population-based interventions to increase coverage of vac-
cines recommended for routine use among children, ado-
lescents, and adults. A total of 197 articles were identified
that evaluated a relevant intervention, met inclusion crite-
ria, and were published during 1980–1997. Reviews of 17
specific interventions were published in 1999 (174–176).
Using the results of their review, the Task Force made rec-
ommendations regarding the use of these interventions
(177). A number of interventions were identified and rec-
ommended on the basis of published evidence. The inter-
ventions and the recommendations are summarized in this
report (Table 7).
TABLE 7. Summary of recommendations regarding interventions to improve coverage of vaccines recommended for routine use
among children, adolescents, and adults*
Intervention Recommendation
Interventions that increase community demand for immunizations
Client reminder or recall systems Strongly recommended
Multicomponent interventions, including education Strongly recommended
School-, child care-, and college-entry requirements Recommended
Community education alone Insufficient evidence
Clinic-based education Insufficient evidence
Patient or family incentives or sanctions Insufficient evidence
Client-held medical records Insufficient evidence
Interventions that enhance access to vaccination services
Reducing out-of-pocket costs Strongly recommended
Enhancing access through the U.S. Department of Recommended
Agriculture’s Women, Infants, and Children program
Home visits, outreach, and case management Recommended
Enhancing access at child care centers Insufficient evidence
Enhancing access at schools Insufficient evidence
Expanding access in health-care settings Recommended as part of multicomponent interventions only
Interventions that target providers
Reminder or recall systems Strongly recommended
Assessment and feedback Strongly recommended
Standing orders Strongly recommended
Provider education alone Insufficient evidence
* Adapted from Task Force on Community Preventive Services. Recommendations regarding interventions to improve vaccination coverage in children,
adolescents, and adults. Am J Prev Med 2000;18(1 Suppl):92–6.
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Vaccine Information Sources
In addition to these general recommendations, other
sources are available that contain specific and updated vac-
cine information.
National Immunization Information
Hotline
The National Immunization Information Hotline is sup-
ported by CDC’s National Immunization Program and pro-
vides vaccination information for health-care providers and
the public, 8:00 am–11:00 pm, Monday–Friday:
Telephone (English): 800-232-2522
Telephone (Spanish): 800-232-0233
Telephone (TTY): 800-243-7889
Internet: http://www.ashastd.org
(accessed November 7, 2001)
CDC’s National Immunization Program
CDC’s National Immunization Program website provides
direct access to immunization recommendations of the Advi-
sory Committee on Immunization Practices (ACIP), vaccina-
tion schedules, vaccine safety information, publications,
provider education and training, and links to other
immunization-related websites. It is located at http://
www.cdc.gov/nip (accessed November 7, 2001).
Morbidity and Mortality Weekly Report
ACIP recommendations regarding vaccine use, statements
of vaccine policy as they are developed, and reports of specific
disease activity are published by CDC in the Morbidity and
Mortality Weekly Report (MMWR) series. Electronic
subscriptions are free and available at http://www.cdc.gov/
subscribe.html (accessed November 7, 2001). Printed sub-
scriptions are available at
Superintendent of Documents
U.S. Government Printing Office
Washington, D.C. 20402-9235
American Academy of Pediatrics (AAP)
Every 3 years, AAP issues the Red Book: Report of the Com-
mittee on Infectious Diseases, which contains a composite sum-
mary of AAP recommendations concerning infectious diseases
and immunizations for infants, children, and adolescents.
Telephone: 888-227-1770
Internet: http://www.aap.org
(accessed November 7, 2001)
American Academy of Family
Physicians (AAFP)
Information from the professional organization of family
physicians is available at http://www.aafp.org (accessed No-
vember 7, 2001).
Immunization Action Coalition
This source provides extensive free provider and patient
information, including translations of Vaccine Information
Statements into multiple languages. The Internet address
is http://www.immunize.org (accessed November 7, 2001).
National Network for Immunization
Information
This information source is provided by the Infectious Dis-
eases Society of America, Pediatric Infectious Diseases Society,
AAP, American Nurses Association, and other professional
organizations. It provides objective, science-based information
regarding vaccines for the public and providers. The Internet
site is http://www.immunizationinfo.org (accessed November
7, 2001).
Vaccine Education Center
Located at the Children’s Hospital of Philadelphia, this source
provides patient and provider information. The Internet ad-
dress is http://www.vaccine.chop.edu (accessed November 7,
2001).
Institute for Vaccine Safety
Located at Johns Hopkins University School of Public
Health, this source provides information regarding vaccine
safety concerns and objective and timely information to health-
care providers and parents. It is available at http://
www.vaccinesafety.edu (accessed November 7, 2001).
National Partnership for Immunization
This national organization encourages greater acceptance and
use of vaccinations for all ages through partnerships with pub-
lic and private organizations. Their Internet address is http://
www.partnersforimmunization.org (accessed November 7,
2001).
State and Local Health Departments
State and local health departments provide technical advice
through hotlines, electronic mail, and Internet sites, includ-
ing printed information regarding vaccines and immunization
schedules, posters, and other educational materials.
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nical errors in vaccine preparation, handling, or adminis-
tration; 4) coincidental: associated temporally with vacci-
nation by chance or caused by underlying illness. Special
studies are needed to determine if an adverse event is a reac-
tion or the result of another cause (Sources: Chen RT. Spe-
cial methodological issues in pharmacoepidemiology studies
of vaccine safety. In: Strom BL, ed. Pharmacoepidemiology.
3rd ed. Sussex, England: John Wiley & Sons, 2000:707–
32; and Fenichel GM, Lane DA, Livengood JR, Horwitz
SJ, Menkes JH, Schwartz JF. Adverse events following im-
munization: assessing probability of causation. Pediatr
Neurol 1989;5:287–90).
Adverse reaction. An undesirable medical condition that
has been demonstrated to be caused by a vaccine. Evidence
for the causal relationship is usually obtained through ran-
domized clinical trials, controlled epidemiologic studies,
isolation of the vaccine strain from the pathogenic site, or
recurrence of the condition with repeated vaccination (i.e.,
rechallenge); synonyms include side effect and adverse ef-
fect).
Immunobiologic. Antigenic substances (e.g., vaccines and
toxoids) or antibody-containing preparations (e.g., globu-
lins and antitoxins) from human or animal donors. These
products are used for active or passive immunization or
therapy. The following are examples of immunobiologics:
Vaccine. A suspension of live (usually attenuated) or
inactivated microorganisms (e.g., bacteria or viruses) or
fractions thereof administered to induce immunity and
prevent infectious disease or its sequelae. Some vaccines
contain highly defined antigens (e.g., the polysaccha-
ride of Haemophilus influenzae  type b or the surface
antigen of hepatitis B); others have antigens that are
complex or incompletely defined (e.g., killed Bordetella
pertussis  or live attenuated viruses).
Toxoid. A modified bacterial toxin that has been
made nontoxic, but retains the ability to stimulate the
formation of antibodies to the toxin.
Immune globulin. A sterile solution containing an-
tibodies, which are usually obtained from human blood.
It is obtained by cold ethanol fractionation of large pools
of blood plasma and contains 15%–18% protein. In-
tended for intramuscular administration, immune
globulin is primarily indicated for routine maintenance
of immunity among certain immunodeficient persons
and for passive protection against measles and
hepatitis A.
Intravenous immune globulin. A product derived
from blood plasma from a donor pool similar to the
immune globulin pool, but prepared so that it is suit-
Abbreviations Used
in This Publication
AAFP American Academy of Family Physicians
AAP American Academy of Pediatrics
ACIP Advisory Committee on Immunization Practices
DT pediatric diphtheria-tetanus toxoid
DTaP diphtheria and tetanus toxoids and acellular
pertussis vaccine
DTP diphtheria and tetanus toxoids and whole-cell
pertussis vaccine
EIA/ELISA enzyme immunoassay
FDA Food and Drug Administration
GBS Guillain-Barré syndrome
HBIG hepatitis B immune globulin
HbOC diphtheria CRM
197
 (CRM, cross-reactive
material) protein conjugate
HBsAg hepatitis B surface antigen
Hib Haemophilus influenzae  type b
HIV human immunodeficiency virus
HSCT hematopoietic stem cell transplant
IgG immunoglobulin G
IGIV intravenous immune globulin
IPV inactivated poliovirus vaccine
JIs jet injectors
MMR measles, mumps, rubella vaccine
OPV oral poliovirus vaccine
OSHA Occupational Safety and Health Administration
PCV pneumococcal conjugate vaccine
PPD purified protein derivative
PRP-OMP polyribosylribitol phosphate-meningococcal
outer membrane protein
PRP-T PRP-tetanus
PPV pneumococcal polysaccharide vaccine
Td adult tetanus-diphtheria toxoid
VAERS Vaccine Adverse Event Reporting System
VAPP vaccine-associated paralytic polio
Definitions Used in This Report
Adverse event. An untoward event that occurs after a vac-
cination that might be caused by the vaccine product or
vaccination process. It includes events that are 1) vaccine-
induced: caused by the intrinsic characteristic of the vac-
cine preparation and the individual response of the vaccinee;
these events would not have occurred without vaccination
(e.g., vaccine-associated paralytic poliomyelitis); 2) vaccine-
potentiated: would have occurred anyway, but were pre-
cipitated by the vaccination (e.g., first febrile seizure in a
predisposed child); 3) programmatic error: caused by tech-
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able for intravenous use. Intravenous immune globulin
is used primarily for replacement therapy in primary
antibody-deficiency disorders, for treatment of Kawasaki
disease, immune thrombocytopenic purpura,
hypogammaglobulinemia in chronic lymphocytic leu-
kemia, and certain cases of human immunodeficiency
virus infection (Table 2).
Hyperimmune globulin (specific). Special prepara-
tions obtained from blood plasma from donor pools
preselected for a high antibody content against a spe-
cific antigen (e.g., hepatitis B immune globulin, vari-
cella-zoster immune globulin, rabies immune globulin,
tetanus immune globulin, vaccinia immune globulin,
cytomegalovirus immune globulin, respiratory syncy-
tial virus immune globulin, botulism immune globu-
lin).
Monoclonal antibody. An antibody product prepared
from a single lymphocyte clone, which contains only
antibody against a single microorganism.
Antitoxin. A solution of antibodies against a toxin.
Antitoxin can be derived from either human (e.g., teta-
nus antitoxin) or animal (usually equine) sources (e.g.,
diphtheria and botulism antitoxin). Antitoxins are used
to confer passive immunity and for treatment.
Vaccination and Immunization. The terms vaccine  and
vaccination  are derived from vacca, the Latin term for cow.
Vaccine  was the term used by Edward Jenner to describe
material used (i.e., cowpox virus) to produce immunity to
smallpox. The term vaccination  was used by Louis Pasteur
in the 19th century to include the physical act of adminis-
tering any vaccine or toxoid. Immunization  is a more inclu-
sive term, denoting the process of inducing or providing
immunity by administering an immunobiologic. Immuni-
zation can be active or passive. Active immunization  is the
production of antibody or other immune responses through
administration of a vaccine or toxoid. Passive immunization
means the provision of temporary immunity by the admin-
istration of preformed antibodies. Four types of
immunobiologics are administered for passive immuniza-
tion: 1) pooled human immune globulin or intravenous
immune globulin, 2) hyperimmune globulin (specific)
preparations, 3) monoclonal antibody preparations, and 4)
antitoxins from nonhuman sources. Although persons of-
ten use the terms vaccination  and immunization  inter-
changeably in reference to active immunization, the terms
are not synonymous because the administration of an
immunobiologic cannot be equated automatically with de-
velopment of adequate immunity.
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1. Which of the following is not a vaccination provider requirement as
specified by the National Childhood Vaccine Injury Act of 1986?
A. Provide a copy of the relevant current edition of the Vaccine
Information Statement before each dose of vaccine.
B. Obtain a signed consent before administration of vaccine.
C. Record information regarding the vaccine in the recipient’s permanent
medical record.
D. Report certain vaccine adverse events to the Vaccine Adverse Event
Reporting System (VAERS).
E. All of the above are required by the National Childhood Vaccine
Injury Act of 1986.
2. What is the preferred option for spacing of tuberculin skin testing
(purified protein derivative [PPD]) and administration of measles-
containing vaccine?
A. PPD and measles-containing vaccine administered at the same visit.
B. PPD administered 72 hours before measles-containing vaccine.
C. PPD administered 4 weeks before measles-containing vaccine.
D. Measles-containing vaccine administered 72 hours before PPD.
E. Measles-containing vaccine administered 4 weeks before PPD.
3. What is the minimum age for administration of the second dose of
inactivated poliovirus vaccine?
A. Four weeks.
B. Six weeks.
C. Ten weeks.
D. Sixteen weeks.
E. Twenty-four weeks.
4. A recent transfusion of whole blood is most likely to interfere with the
response to which of the following vaccines?
A. Inactivated poliovirus vaccine.
B. Yellow fever vaccine.
C. Hepatitis B vaccine.
D. Measles vaccine.
E. Adult formulation of tetanus-diphtheria toxoid.
5. Which of the following is a valid contraindication to the
administration of varicella vaccine?
A. Pregnancy.
B. Child who is being breast-fed.
C. Immunodeficient sibling living in the household.
D. Current antibiotic therapy.
E. All of the above are valid contraindications to the administration of
varicella vaccine.
6. What action is recommended if varicella vaccine is inadvertently
administered 10 days after a dose of measles-mumps-rubella (MMR)
vaccine?
A. Repeat both vaccines >4 weeks after the varicella vaccine was
administered.
B. Repeat only the MMR vaccine >4 weeks after the varicella.
C. Repeat only the varicella vaccine >4 weeks after the inadvertently
administered dose of varicella vaccine.
D. Repeat only the varicella vaccine >6 months after the inadvertently
administered dose of varicella vaccine.
E. No action is recommended; both doses are counted as valid.
Goal and Objectives
This MMWR provides general guidelines on immunizations. These recommendations were developed by CDC staff, the Advisory Committee on Immunization Practices
(ACIP), and the American Academy of Family Physicians (AAFP). The goal of this report is to improve vaccination practices in the United States. Upon completion of this
activity, the reader should be able to a) identify valid contraindications and precautions for commonly used vaccines; b) locate the minimum age and minimum spacing
between doses for vaccines routinely used in the United States; c) describe recommended methods for administration of vaccines; and d) list requirements for vaccination
providers as specified by the National Childhood Vaccine Injury Act of 1986.
To receive continuing education credit, please answer all of the following questions.
7. What is the minimum needle length recommended for intramuscular
injection of an infant?
A. ½ inch.
B. 5/8 inch.
C. 7/8 inch.
D. 1 inch.
E. 1¼ inch.
8. Which of the following approaches is recommended for the
vaccination of a person with substantial immunodeficiency?
A. Inactivated vaccine should be administered as indicated without
regard to the immunodeficiency.
B. Live attenuated viral vaccines should generally not be administered to
persons with severe immunodeficiency.
C. Persons with humoral immunodeficiency should receive varicella
vaccine if indicated.
D. Live attenuated viral vaccines should be administered to susceptible
household contacts of immunodeficient persons.
E. All of the above are approaches recommended for the vaccination of a
person with substantial immunodeficiency.
9. What action is recommended if the interval between doses of hepatitis
B vaccine is longer than the recommended interval?
A. Add one additional dose.
B. Add two additional doses.
C. Restart the series from the beginning.
D. Perform a serologic test to determine if a response to the vaccine has
been obtained.
E. Continue the series, ignoring the prolonged interval.
10. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other work setting.
11. Which best describes your professional activities?
A. Patient care — emergency or urgent care.
B. Patient care — inpatient.
C. Patient care — primary care clinic or office.
D. Laboratory or pharmacy.
E. Public health.
F. Other.
12. I plan to use these recommendations as the basis for . . . (Indicate all
that apply.)
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other uses.
13. Have you administered >1 doses of vaccine in the last 12 months?
A. Yes.
B. No.
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14. How much time did you spend reading this report and completing the
exam and evaluation?
A. Less than 2 hours.
B. 2–2.5 hours.
C. 2.5–3 hours.
D. More than 3 hours.
15. After reading this report, I am confident I can identify valid
contraindications and precautions for commonly used vaccines.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
16. After reading this report, I am confident I can locate the minimum age
and minimum spacing between doses for vaccines routinely used in
the United States.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
17. After reading this report, I am confident I can describe recommended
methods for administration of vaccines.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
18. After reading this report, I am confident I can list requirements for
vaccination providers as specified by the National Childhood Vaccine
Injury Act of 1986.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
19. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
20. The tables are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
21. Overall, the format of the report enhanced my ability to understand
the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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Correct answers for questions 1–9
1. B; 2. A; 3. C; 4. D; 5. A; 6. C; 7. C; 8. E; 9. E.
22. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
23. The availability of continuing education credit influenced my decision
to read this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. How did you learn about this continuing education activity?
A. Internet.
B. Advertisement (e.g., fact sheet, MMWR  cover, newsletter, or journal).
C. Coworker/supervisor.
D. Conference presentation.
E. MMWR  subscription.
F. Other.
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